Hsp90 (heat shock protein 90) is a chaperone protein that assists other proteins to fold properly, stabilizes proteins against heat stress, and aids in protein degradation. It also stabilizes a number of proteins required for tumor growth, which is why Hsp90 inhibitors are investigated as anti-cancer drugs.

Heat shock proteins, as a class, are among the most highly expressed cellular proteins across all species.^[3] As their name implies, heat shock proteins protect cells when stressed by elevated temperatures. They account for 1–2% of total protein in unstressed cells. However, when cells are heated, the fraction of heat shock proteins increases to 4–6% of cellular proteins.^[4]

Heat shock protein 90 (Hsp90) is one of the most common of the heat-related proteins. The “90” comes from the fact that it weighs roughly 90 kiloDaltons. A 90 kDa protein is considered fairly large for a non-fibrous protein. Hsp90 is found in bacteria and all branches of eukarya, but it is apparently absent in archaea.^[5] Whereas cytoplasmic Hsp90 is essential for viability under all conditions in eukaryotes, the bacterial homologue HtpG is dispensable under non-heat stress conditions.^[6]

This protein was first isolated by extracting proteins from cells stressed by heating, dehydrating or by other means, all of which caused the cell’s proteins to begin to denature.^[7] However it was later discovered that Hsp90 also has essential functions in unstressed cells. -wiki

SCIENTIFIC STUDIES

1. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
2. Inhibiting the Hsp90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
3. Inhibiting Hsp90 to treat cancer: a strategy in evolution
4. Molecular simulation of HER2/neu degradation by inhibiting HSP90
5. Inhibiting the Hsp90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease
6. Black tea polyphenols induce human leukemic cell cycle arrest by inhibiting Akt signaling: Possible involvement of Hsp90, Wnt/β‐catenin signaling and FOXO1
7. Microparticles from patients with the acute coronary syndrome impair vasodilatation by inhibiting the Akt/eNOS-Hsp90 signaling pathway
8. Cks1 proteasomal degradation is induced by inhibiting Hsp90-mediated chaperoning in cancer cells
9. Inhibiting the molecular evolution of cancer through HSP90
10. A chemical compound inhibiting the Aha1–Hsp90 chaperone complex
11. Hsp90 is a novel target molecule of CDDO-Me in inhibiting proliferation of ovarian cancer cells
12. Inhibiting heat shock protein 90 (Hsp90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice
13. Inhibiting Hsp90 prevents the induction of myeloid-derived suppressor cells by melanoma cells
14. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways
15. Uncaria rhynchophylla Ameliorates Parkinson’s Disease by Inhibiting Hsp90 Expression: Insights from Quantitative Proteomics
16. Targeting Hsp90-Cdc37: a promising therapeutic strategy by inhibiting Hsp90 chaperone function
17. Combination Immunotherapy of Melanoma by inhibiting Hsp90 and targeting its client proteins.(TUM7P. 934)
18. Influence of co-inhibiting mTORC2 and Hsp90 on proliferation apoptosis of multiple myeloma cells
19. Hsp90 inhibiting anti-cancer therapeutics enhance bone loss by increasing osteoclast formation: Mechanism of action.
20. Abstract# 1854: Superoxide-dependent hepatotoxicity of the Hsp90 inhibiting anticancer drugs geldanamycin and its two derivatives
21. Development of Small Molecules Blocking Glucose Transporter Or Inhibiting Hsp90 for the Therapy of Cancer
22. Gambogic acid attenuates liver fibrosis by inhibiting the PI3K/AKT and MAPK signaling pathways via inhibiting HSP90
23. Ritonavir inhibits breast cancer cell proliferation, in part, by inhibiting Hsp90 function and Akt phosphorylation
24. The effect of curcumin on bortezomib by inhibiting Hsp90 of myeloma MM1. R
25. Diosgenin suppressed LPS-induced inflammation through inhibiting Hsp90 induced phosphorylation of NF-κb p65
26. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer
27. Inhibiting protein-protein interactions in Hsp90 dimerization as a novel approach for targeting cancer
28. Characterization of celastrol to inhibit Hsp90 and cdc37 interaction
29. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase
30. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery
31. Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin
32. Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells
33. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
34. Hsp90 blockers inhibit adipocyte differentiation and fat mass accumulation
35. Cyclic lipopeptide antibiotics bind to the N-terminal domain of the prokaryotic Hsp90 to inhibit the chaperone activity
36. New, Non‐quinone Fluorogeldanamycin Derivatives Strongly Inhibit Hsp90
37. Ca2+/S100 proteins inhibit the interaction of FKBP38 with Bcl-2 and Hsp90
38. 2D-QSAR of purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells
39. Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug …
40. Single-walled carbon nanotubes (SWCNTs) inhibit heat shock protein 90 (Hsp90) signaling in human lung fibroblasts and keratinocytes
41. Sarqaquinoic acid and related synthetic naphthoquinones inhibit the function of Hsp90
42. Deguelin analogues, L80 and SH-1242, inhibit Hsp90 activity and exert potent anticancer efficacy with limited toxicities in non-small cell lung cancer (NSCLC)
43. Abstract B80: Hsp90 inhibitor SNX‐2112 and prodrug SNX‐5422 (PF‐04929113) inhibit key signal pathways Akt, Src and STAT3 and reactivate tumor suppressor …http://mct.aacrjournals.org/content/8/12_Supplement/B80.short
44. Hsp90 inhibition decreases mitochondrial protein turnover
45. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress
46. Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition
47. Inhibition of Hsp90: a multitarget approach to radiosensitization
48. Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IκB kinase (IKK)
49. Hsp90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer …
50. Hsp90 inhibition: two-pronged exploitation of cancer dependencies
51. 17 AAG for Hsp90 inhibition in cancer-from bench to bedside
52. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation
53. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses
54. Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response
55. Hsp90 modulates actin dynamics: inhibition of Hsp90 leads to decreased cell motility and impairs invasion
56. … reticulum vacuolization and valosin-containing protein relocalization result from simultaneous Hsp90 inhibition by geldanamycin and proteasome inhibition by …
57. To fold or not to fold: modulation and consequences of Hsp90 inhibition
58. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives
59. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition
60. Inhibition of Hsp90 in Trypanosoma cruzi induces a stress response but no stage differentiation
61. Hsp90 Inhibition with Resorcylic Acid Lactones (RALs)
62. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition
63. Targeting HSF1 sensitizes cancer cells to Hsp90 inhibition
64. Combined EGFR/MET or EGFR/Hsp90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET
65. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis
66. Hsp90 inhibition protects against inherited retinal degeneration
67. FGFR3 translocations in bladder cancer: differential sensitivity to Hsp90 inhibition based on drug metabolism
68. Hsp90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis
69. Targeting multiple signal transduction pathways through inhibition of Hsp90
70. Inhibition of Hsp90 molecular chaperones: moving into the clinic
71. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation
72. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo
73. Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition
74. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic …
75. Heat-induced Oligomerization of the Molecular Chaperone Hsp90 INHIBITION BY ATP AND GELDANAMYCIN AND ACTIVATION BY TRANSITION METAL …
76. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
77. Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in …
78. Inhibition of Hsp90: a new strategy for inhibiting protein kinases
79. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells
80. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the …
81. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
82. Hsp90 inhibition: Elimination of shock and stress
83. Inhibition of MDM2 by Hsp90 contributes to mutant p53 stabilization
84. Inhibition of N-terminal ATPase on Hsp90 attenuates colitis through enhanced Treg function
85. Inhibition of Hsp90 compromises the DNA damage response to radiation
86. Hsp90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
87. Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP
88. Inhibition of ALK, PI3K/MEK, and Hsp90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene
89. Protein kinase CK2 protects multiple myeloma cells from ER stress–induced apoptosis and from the cytotoxic effect of Hsp90 inhibition through regulation of the …
90. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma
91. Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
92. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma
93. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
94. Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic …
95. Hsp90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways
96. Identification of a new scaffold for Hsp90 C-terminal inhibition
97. Hsp90 inhibition protects against biomechanically induced osteoarthritis in rats
98. Therapeutic potential of Hsp90 inhibition for neurofibromatosis type 2
99. Hsp90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy
100. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis
101. Induction of premature senescence by Hsp90 inhibition in small cell lung cancer
102. Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis
103. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
104. Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin
105. Efficient synthesis of a novel resorcyclide as anticancer agent based on Hsp90 inhibition
106. Inhibition of heat shock protein 90 (Hsp90) as a therapeutic strategy for the treatment of myeloma and other cancers
107. UBR1 promotes protein kinase quality control and sensitizes cells to Hsp90 inhibition
108. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities
109. Blocking NF-κB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death
110. Hsp90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas
111. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest
112. Hsp90 inhibition and the expression of phenotypic variability in the rainforest species Drosophila birchii
113. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells
114. Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines
115. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone
116. Intrinsic inhibition of the Hsp90 ATPase activity
117. Resistance to Hsp90 inhibition involving loss of MCL1 addiction
118. Hsp90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia
119. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
120. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition
121. Molecular mechanism of inhibition of the human protein complex Hsp90–Cdc37, a kinome chaperone–cochaperone, by triterpene celastrol
122. Inhibition of Hsp90 function delays and impairs recovery from heat shock
123. Hsp90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells
124. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
125. Inhibition of Hsp90 as a special way to inhibit protein kinases
126. Disruption of zebrafish somite development by pharmacologic inhibition of Hsp90
127. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex
128. 18β-Glycyrrhetinic acid potentiates Hsp90 inhibition-induced apoptosis in human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial
129. Effect of heat-shock protein-90 (Hsp90) inhibition on human hepatocytes and on liver regeneration in experimental models
130. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by Hsp90 inhibition
131. Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines
132. Inhibition of Hsp90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer
133. 5-Episinuleptolide acetate, a norcembranoidal diterpene from the formosan soft coral Sinularia sp., induces leukemia cell apoptosis through Hsp90 inhibition
134. Heat shock protein 90 (Hsp90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of …
135. Influence of Hsp90 and HDAC inhibition and tubulin acetylation on perinuclear protein aggregation in human retinal pigment epithelial cells
136. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation
137. Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol
138. Destabilization of PDK1 by Hsp90 inactivation suppresses hepatitis C virus replication through inhibition of PRK2-mediated viral RNA polymerase phosphorylation
139. Pharmacologic and genetic inhibition of Hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor …
140. Inhibition of Hsp90 with Pochoximes: SAR and Structure‐Based Insights
141. Hsp90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo
142. Inhibition of GR‐mediated transcription by p23 requires interaction with Hsp90
143. Inhibition of heat shock protein 90 (Hsp90) in proliferating endothelial cells uncouples endothelial nitric oxide synthase activity
144. Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to Hsp90 inhibition
145. Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells
146. Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition
147. Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G2/M arrest in glioblastoma cell lines
148. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition
149. Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90
150. Inhibition of Hsp90 by AUY922 preferentially kills mutant KRAS colon cancer cells by activating Bim through ER stress
151. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma
152. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
153. Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of Hsp90 inhibition in an in vivo squamous cell carcinoma model
154. Blocking the survival of the nastiest by Hsp90 inhibition
155. Dynamic cycling with Hsp90 stabilizes neuronal nitric oxide synthase through calmodulin-dependent inhibition of ubiquitination
156. Hsp90 inhibition induces both protein-specific and global changes in the ubiquitinome
157. Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma
158. Oxidative inhibition of Hsp90 disrupts the super‐chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo
159. Induction of heat shock protein HSPA6 (HSP70B′) upon Hsp90 inhibition in cancer cell lines
160. Blocking the heat shock response and depleting HSF-1 levels through heat shock protein 90 (Hsp90) inhibition: a significant advance on current Hsp90 …
161. Hsp90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo
162. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
163. Inhibition of Hsp90 could be possible mechanism for anti-cancer property of amniotic membrane
164. Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90
165. Calpain genetic disruption and Hsp90 inhibition combine to attenuate mammary tumorigenesis
166. Hsp90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer
167. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma
168. Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma
169. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA …
170. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration
171. The interplay between inhibition of JAK2 and HSP90
172. Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol
173. Inhibition of cell death by a novel 16.2 kD heat shock protein predominantly via Hsp90 mediated lipid rafts stabilization and Akt activation pathway
174. Hsp90 binds directly to fibronectin (FN) and inhibition reduces the extracellular fibronectin matrix in breast cancer cells
175. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
176. Hsp90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents
177. Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells
178. Synthesis of flavokawain analogues and their anti-neoplastic effects on drug-resistant cancer cells through Hsp90 inhibition
179. Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature
180. Inhibition of Hsp90 with resorcylic acid macrolactones: synthesis and binding studies
181. Combined BRAF and Hsp90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma
182. Down-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells
183. Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities
184. Inhibition of HSP90‐dependent telomerase activity in amyloid β‐induced apoptosis of cerebral endothelial cells
185. Hsp90 inhibition in HER2-positive breast cancer cells
186. Synthesis of butein analogues and their anti-proliferative activity against gefitinib-resistant non-small cell lung cancer (NSCLC) through Hsp90 inhibition
187. Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70
188. Inhibition of heat shock protein 70 and 90 (Hsp70 and Hsp90) in target spesific cancer treatment
189. Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy
190. Combined inhibition of extracellular signal-regulated kinases and Hsp90 sensitizes human colon carcinoma cells to ionizing radiation
191. Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR
192. Identification of mixed lineage leukemia 1 (MLL1) protein as a coactivator of heat shock factor 1 (HSF1) protein in response to heat shock protein 90 (Hsp90) inhibition
193. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma
194. Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
195. Hsp90 inhibition suppresses NF-κB transcriptional activation via Sirt-2 in human lung microvascular endothelial cells
196. Concomitant inhibition of HSP90, its mitochondrial localized homologue TRAP1 and HSP27 by green tea in pancreatic cancer HPAF‐II cells
197. Prospective identification of resistance mechanisms to Hsp90 inhibition in KRAS mutant cancer cells
198. Hsp90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal …
199. Co-inhibition of HSP70/Hsp90 synergistically sensitizes nasopharyngeal carcinoma cells to thermotherapy
200. EGFR Exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas
201. Boosting the effects of hyperthermia-based anticancer treatments by Hsp90 inhibition
202. Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma
203. Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition
204. AIDing cancer treatment: reducing AID activity via Hsp90 inhibition
205. Pharmacological inhibition of Hsp90 and ras activity as a new strategy in the treatment of HNSCC
206. Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses
207. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
208. Pharmacological inhibition of Hsp90 activity negatively modulates myogenic differentiation and cell survival in C2C12 cells
209. Hsp90 inhibition results in glucocorticoid receptor degradation in association with increased sensitivity to paclitaxel in triple-negative breast cancer
210. … β peptide-induced inhibition of endothelial nitric oxide production involves oxidative stress-mediated constitutive eNOS/Hsp90 interaction and disruption of …
211. Hsp90 inhibition renders iNOS aggregation and the clearance of iNOS aggregates by proteasomes requires SPSB2
212. Hsp90 inhibition without heat shock response
213. Hsp90-mediated inhibition of FKBP38 regulates apoptosis in neuroblastoma cells
214. Reactive oxygen species-dependent Hsp90 protein cleavage participates in arsenical As+ 3-and MMA+ 3-induced apoptosis through inhibition of telomerase activity …
215. Sulphoxythiocarbamates modify cysteine residues in Hsp90 causing degradation of client proteins and inhibition of cancer cell proliferation
216. Inhibition of Hsp90 attenuates porcine reproductive and respiratory syndrome virus production in vitro
217. Magnetic nanoparticle-mediated hyperthermia therapy induces tumour growth inhibition by apoptosis and Hsp90/AKT modulation
218. Changes in heat-shock protein synthesis and thermotolerance of Arabodopsis thaliana seedlings resulting from Hsp90 inhibition by geldanamycin
219. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib …
220. Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma
221. Inhibition of Plasmodium falciparum Hsp90 Contributes to the Antimalarial Activities of Aminoalcohol-carbazoles
222. Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion
223. Hsp90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome
224. Strong antitumor synergy between DNA crosslinking and Hsp90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells
225. Inhibition and flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced …
226. Inhibition of Hsp90 attenuates pro-inflammatory cytokines and prevents LPS induced liver injury
227. Little effect of Hsp90 inhibition on the quantitative wing traits variation in Drosophila melanogaster
228. Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a Hsp90-dependent manner
229. Tomato plant cell death induced by inhibition of Hsp90 is alleviated by Tomato yellow leaf curl virus infection
230. Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy
231. Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro
232. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer
233. Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG
234. Efficacy of Hsp90 inhibition for the induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo
235. In silico investigations on Hsp90 and its inhibition for the therapeutic prevention of breast cancer
236. … not HSP90, confers neuroprotection against fatal endotoxemia via augmentation of nitric-oxide synthase I (NOS I)/protein kinase G signaling pathway and inhibition of …
237. Hsp90 inhibition suppresses PGE2 production via modulating COX-2 and 15-PGDH expression in HT-29 colorectal cancer cells
238. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells
239. Targeting the MYC oncogene in Burkitt lymphoma through Hsp90 inhibition
240. Hsp90 inhibition induces destabilization of actin cytoskeleton in tumor cells: functional significance of Hsp90 interaction with F–actin
241. Ascorbic acid inhibition of Candida albicans Hsp90-mediated morphogenesis occurs via the transcriptional regulator Upc2
242. The targeted inhibition of mitochondrial Hsp90 overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis
243. Bioactive metabolites from Chaetomium aureum: Structure elucidation and inhibition of the Hsp90 machine chaperoning activity
244. Heat shock protein 90 (Hsp90) inhibition in acute myeloid leukemia—Targeting of disease heterogeneity through direct and indirect antileukemic effects
245. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging
246. Selective Inhibition of HDAC6 regulates preferential cytotoxicity in cancer cells by modulating p53 and Hsp90 stability
247. 2-Aroylquinoline-5, 8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (Hsp90) inhibition
248. Epigenetic effects of inhibition of heat shock protein 90 (Hsp90) in human pancreatic and colon cancer
249. Quantitative proteomics reveals molecular mechanism of gamabufotalin and its potential inhibition on Hsp90 in lung cancer
250. Hsp90 inhibition affects cell metabolism by disrupting mitochondrial protein insertion
251. Drug-induced Hsp90 inhibition alleviates pain in monoarthritic rats and alters the expression of new putative pain players at the DRG
252. Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane
253. Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines.
254. Hyponatremia and V2 vasopressin receptor upregulation: a result of Hsp90 inhibition
255. Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90
256. … inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 …
257. Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome
258. Hsp90 inhibition drives degradation of FGFR2 fusion proteins: Implications for treatment of cholangiocarcinoma
259. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation
260. Inhibition of Heat Shock proteins Hsp90 and HSP70 induce oxidative stress, suppressing cotton fiber development
261. Hsp90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC
262. MicroPET/CT imaging of AXL downregulation by Hsp90 inhibition in triple-negative breast cancer
263. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
264. Radicicol binding to Swo1/Hsp90 and inhibition of growth of specific temperature-sensitive cell cycle mutants of fission yeast
265. Hsp90 inhibition results in a significant delay in tumor progression in a model of emerging EGFR TKI resistance in non-small cell lung cancer
266. Inhibition of Hsp90 promotes neural stem cell survival from oxidative stress through attenuating NF-κB/p65 activation
267. … docking analysis of the molecular chaperone-kinase interactions: Towards allosteric inhibition of protein kinases by targeting the Hsp90-Cdc37 chaperone machinery
268. Phenotypic variability of Arabidopsis thaliana seedlings as a result of inhibition of Hsp90 chaperones
269. Antiangiogenic effects associated with the inhibition of Hsp90 in colorectal cancer
270. Hsp90 inhibition is a potential therapeutic strategy in treatment of adenocarcinoma of the esophagus
271. Hsp90 inhibition as an anticancer strategy: Novel approaches and future directions
272. 17-DMAG-loaded nanofibrous scaffold for effective growth inhibition of lung cancer cells through targeting Hsp90 gene expression
273. Geldanamycin derivatives as promising anticancer drugs: therapy via Hsp90 inhibition
274. Effect of Hsp90 inhibition on Rac activation, cell migration, tumor growth and liver metastasis of human pancreatic carcinoma
275. Targeted inhibition of mitochondrial Hsp90 induces mitochondrial elongation in Hep3B hepatocellular carcinoma cells undergoing apoptosis by increasing …
276. Traditional and novel mechanisms of heat shock protein 90 (Hsp90) inhibition in cancer chemotherapy including Hsp90 cleavage
277. Simultaneous inhibition of Hsp90 and mTOR synergistically reduces tumor growth and angiogenesis of hepatocellular cancer in an experimental model
278. … sesterterpenoid-type metabolite, induces apoptosis in prostate LNcap cells via oxidative and ER stress combined with the inhibition of topoisomerase II and Hsp90
279. AMH and AMHR2 regulate survival signaling, epithelial-mesenchymal transition (EMT) and resistance to Hsp90 inhibition in non-small cell lung cancer (NSCLC)
280. Hsp90 Inhibition Reduces TLR5 Surface Expression and NF-κB Activation in Human Myeloid Leukemia THP-1 Cells
281. Overcoming acquired resistance to Hsp90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
282. Evaluating dual Hsp90 and Hsp70 inhibition as a cancer therapy
283. Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition
284. Correction: Strong antitumor synergy between DNA crosslinking and Hsp90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells
285. Changes in heat shock protein synthesis and thermotolerance of Arabidopsis thaliana seedlings as a result of inhibition of Hsp90 by geldanamycin
286. Novel and less explored chemotypes of natural origin for the inhibition of Hsp90
287. Hsp90 inhibition attenuates LPS-mediated NF-κB-dependent gene activation by preventing the de-acetylation and maintaining the DNA binding of acetyl-histone H3 …
288. Hsp90-mediated inactivation of NF {kappa} B switches autophagy to apoptosis through becn1 transcriptional inhibition in selenite-induced NB4 cells
289. … yeast into whether the rapamycin inhibition of heat shock transcription factor (Hsf1) can prevent the Hsf1 activation that results from treatment with an Hsp90 …
290. Celastrol Mediated Hsp90 Protein Inhibition in Cancer
291. Downregulation of androgen receptors by NaAsO2 via inhibition of AKT‐NF‐κB and Hsp90 in castration resistant prostate cancer
292. Transcriptomics-based screening identifies pharmacological inhibition of Hsp90 as a means to defer aging
293. Enhanced HIF1α inhibition through dual inhibition of CDK and HSP90
294. Hsp90 N-and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells
295. Inhibition of Hsp90 by triptolide (TPL) augments Bortezomib-induced U266 cells apoptosis
296. Hsp90 inhibition promotes proteasome function in vascular endothelial cells
297. Inhibition of elemene on Hsp90/Raf-1 molecular complex in C6 glioblastoma cells [J]
298. Targeted Inhibition Of Mitochondrial Hsp90 Improves Pulmonary Arterial Hypertension
299. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs
300. Epilepsy: Hsp90 inhibition suppresses seizures
301. A scaffold merging approach to Hsp90 C-terminal inhibition: synthesis and evaluation of a chimeric library
302. Hsp90 Inhibition Reverts IL13-and IL17-Induced Goblet Cell Metaplasia in Human Airway Epithelia
303. INVESTIGATION OF THE CELLULAR EFFECTS OF Hsp90 INHIBITION ON HEPATOCELLULAR CARCINOMA CELLS
304. RNAi knockdown or chemical inhibition of anaphase-promoting complex components is synthetic lethal with Hsp90 inhibition
305. Inhibition Of Hsp90 Repairs The LPS-Induced Ali In Mice
306. A comprehensive study to analyze tumor sensitivity to Hsp90 inhibition therapy.
307. Trypanosoma cruzi Inhibition of Hsp90 in
308. Acquired resistance to Hsp90 inhibition in triple-negative breast cancer
309. Inhibition of Hsp90 in Streptomyces coelicolor
310. Hsp90 inhibition affects MHC class II presentation of glutamic acid decarboxylase
311. Role of PRKD2 in Hsp90 inhibition-mediated suppression of cancer growth
312. MRS detection of altered choline metabolism following Hsp90 inhibition
313. Hsp90 inhibition radiosensitize head and neck carcinoma via EGFR degradation
314. Impact of Hsp90 Inhibition on Viability and Cell Cycle in Relation to p53 Status
315. Preclinical efficacy of Hsp90 inhibition by using PF-04942847 in osteosarcoma
316. CLU inhibition using OGX-011 is a new adjuvant therapeutic strategy for Hsp90 inhibition in prostate cancer
317. Dual inhibition of CDK1 and Hsp90 destabilizes HIF1α and synergistically induces cancer cell death
318. Functional inhibition of Hsp90 potentiates the effects of ionizing radiation in colorectal cancer
319. Combining Hsp90 Inhibition with Standard Therapies for HER2 Positive Breast Cancer.
320. The new molecular target therapy of Hsp90 inhibition in esophageal squamous cell carcinoma
321. Hsp90 inhibition decreases ovarian cancer cell proliferation and potentiates platinum sensitivity
322. Hsp90 inhibition down regulates EGFR and its effector signaling proteins in pancreatic cancer cell lines
323. Synthetic lethal screen identifies candidates that modulate cancer cell sensitivity in response to Hsp90 inhibition.
324. CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for Hsp90 inhibition in prostate cancer.
325. Inhibition of Hsp90 suppresses BmNPV replication in Bombyx mori
326. … : Modulation of the Hsp90 cochaperone carboxy‐terminus HSC70‐interacting protein (CHIP) increases cellular sensitivity to heat shock protein 90 (Hsp90) inhibition
327. Heat shock protein 90 (Hsp90) inhibition reduces glomerular filtration rate (GFR) and sodium excretion.
328. Changes in choline metabolism as potential biomarkers of Hsp90 inhibition in NEU/HER2-driven mammary carcinoma Oncomouse® cells
329. Hsp90 acetylation following histone deacetylase inhibition: A role for the histone acetyltransferases p300 and PCAF
330. A67 BREAKDOWN: THE CELLULAR CONTRIBUTION TO PULMONARY HYPERTENSION: Targeted Inhibition Of Mitochondrial Hsp90 Improves Pulmonary Arterial …
331. HDAC and Hsp90 inhibition as therapeutic strategy for translocation renal cell carcinoma
332. Hsp90 inhibition leads to a differential proteomics profile in non small cell lung cancer cell lines
333. THU0057 Inhibition of Heat Shock Protein 90 (Hsp90) Prevents Fibrosis by Targeting Canonical TGF-B Signaling
334. Immunostimulatory effects of Hsp90 inhibition: Insights from combinational immunotherapies targeting EphA2
335. Proteomic analysis of ubiquitination identifies the interplay between Hsp90 inhibition and CUL5 in the control of autophagy
336. TREATMENT OF AVIAN TIBIAL DYSCHONDROPLASIA USING TRADITIONAL CHINESE MEDICINES BY Hsp90 INHIBITION
337. Supplementary Materials: Targeting the MYC Oncogene in Burkitt Lymphoma through Hsp90 Inhibition
338. Abstract B16: Phenotypic plasticity in the EML cell culture system as a result of Hsp90 inhibition
339. Visualizing dual downregulation of IGF-1R and VEGF by Hsp90 inhibition effect in triple negative breast cancer
340. Hsp90 Inhibition Leads to the Degradation of O-Linked N-Acetylglucosamine Transferase and to the Reduction of O-GlcNAcylation
341. Effect of Hsp90 inhibition in tumor cells Apoptosis and cell migration
342. HER2-overexpressing lines are sensitive to Hsp90 inhibition irrespective of p53 status
343. Analysis of cell cycle-related gene expressions in MDM2-transfected LNCaP-MST cells after inhibition of HSP90
344. Inhibition of Hsp90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer
345. Cellular and molecular effects of Hsp90 inhibition by 17-AAG in sporadic and hereditary breast cancer
346. Hsp90 Inhibition and Cellular Stress Elicits Phenotypic Plasticity in Hematopoietic Differentiation
347. Therapeutic inhibition of Hsp90 in a mouse model of diabetic atherosclerosis and nephropathy
348. Slow, tight binding inhibition of Hsp90 isoforms correlates with potent anti-proliferative activity in cancer cell lines
349. Empirical Modeling the Effect of Hsp90 Inhibition on Cytokines Associated With Impaired Biotransport of Apoptotic Debris
350. Effect of Hsp90 inhibition on the gene expression profile of MDM2 transfected LNCaP-MST prostate cancer cells
351. Evaluation of biomarkers for imaging and radio-immunotherapy in combination with Hsp90 inhibition in squamous cell carcinomas
352. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
353. Novobiocin–ferrocene conjugates possessing anticancer and antiplasmodial activity independent of Hsp90 inhibition
354. A62 LUNG FIBROSIS: FIBROBLAST BIOLOGY: Hsp90 Inhibition Prevents Lung Fibroblast Activation And Epithelial-Mesenchymal Transition
355. Abstract P4-16-05: Hsp90 inhibition potentiates chemotherapy effectiveness in triple negative breast cancer: Role of glucocorticoid receptor signaling
356. Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activities
357. Hsp90 inhibition rescues behavioral deficits and reduces tau phosphorylation in ps19 mice model for Alzheimer’s disease (AD)
358. Inhibition of heat shock protein 90 (Hsp90) and degradation of client proteins associated with oncogenesis using analogs of Novobiocin
359. Hsp90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase
360. Hsp90 inhibition ameliorates CD4+ T cell‐mediated acute Graft versus Host disease in mice
361. Hsp90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics
362. Computational modeling of Hsp90 inhibition illustrates a potential therapy to inhibit immune-mediated inflammation in systemic lupus erythematosus.(87.8)
363. Hsp90 inhibition suppresses LPS-mediated NFkB target gene expression without affecting NFkB nuclear translocation in human lung microvascular endothelial cells
364. Hsp90 inhibition induced cytotoxicity via downregulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells
365. Hsp90 inhibition abolishes LPS-mediated NF-κB transcriptional activation independent of IKKβ in human lung microvascular endothelial cells (HLMVEC)(847.7)
366. Hsp90 inhibition prevents bacterial lipopolysaccharide-induced and RhoA-mediated signaling leading to paracellular hyper-permeability in human lung microvascular …
367. USP22-dependent HSP90AB1 expression promotes resistance to Hsp90 inhibition in mammary and colorectal cancer
368. Role for NQO1 and MnSOD in 17AAG-Induced Hsp90 inhibition in Pancreatic Cancer Cells
369. Hsp90 inhibition results in GR, AR and JAK protein degradation, decreased triple-negative breast cancer proliferation and increased paclitaxel sensitivity
370. Hsp90 inhibition prevents monocrotaline-induced pulmonary hypertension in rats, as revealed by high resolution echocardiography
371. Correction: 2-Aroylquinoline-5, 8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (Hsp90) inhibition
372. Compromising the constitutive p16INK4a expression sensitizes human neuroblastoma cells to Hsp90 inhibition and promotes premature senescence
373. Hsp90 Inhibition Enhances the Anti-Tumor Efficacy of Combination Chemo Immunotherapy Targeting DNA Repair Proteins
374. Casting a wide net: Hsp90 inhibition to circumvent resistance to TKIs in EGFR-mutated and ALK-rearranged NSCLC
375. Hsp90 inhibition attenuates the LPS-mediated phosphorylation of CREB and STAT3 in human lung microvascular endothelial cells
376. Ligand-independent activation of the P2X7 receptor by Hsp90 inhibition stimulates motor neuron apoptosis
377. Abstract# 2835: Inhibition of heat shock protein 90 (Hsp90) modulates macrophage stimulating-1 receptor (MSR1) expression and signaling, and reduces pancreatic …
378. Pharmacological Inhibition of Hsp90 as a Novel Antitumor Strategy to Target Cytoarchitecture Through Extracellular Matrix Signaling
379. Metabolic profiling of drug response in prostate cancer cells following PI3K, MAPK and Hsp90 inhibition using magnetic resonance spectroscopy
380. 17-AAG Hsp90 Inhibition as an Effective Therapy for Lymphoma Stem Cells.
381. Chemical inhibition of Hsp90 inhibits TNF‐α mediated proliferation and induces apoptosis in human rheumatoid arthritis fibroblast‐like synoviocytes
382. Integration of Hsp90 inhibition in combinational immunotherapies targeting receptor tyrosine kinase EphA2
383. 17-AAG Mediated Hsp90 Inhibition as an Effective Therapy for Lymphoma Stem Cells
384. A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to Hsp90 Inhibition
385. Visualizing dual downregulation of IGF-1 R and VEGF-A by Hsp90 inhibition effect in triple negative breast cancer
386. Abstract A226: ImmunoPET with 89Zr‐DFO‐trastuzumab: Monitoring the pharmacodynamic effects on HER2/neu expression by Hsp90 inhibition in vivo
387. Effects of Hsp90 inhibition and/or PKC activation on ErbB2 in MDA-MB-453 cells
388. Abstract B103: Hsp90 inhibition targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell carcinoma …
389. Abstract P1-03-07: Differential Effect of Specific p53 Mutations on Breast Cancer Growth and Response to Hsp90 Inhibition In Vivo
390. … # 4975: Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat shock protein 90 (Hsp90) inhibition
391. Effect of heat stress and Hsp90 inhibition on T-type calcium currents and voltage-dependent potassium currents in leydig cells
392. This is a repository copy of FGFR3 translocations in bladder cancer: differential sensitivity to Hsp90 inhibition based on drug metabolism..
393. B28 BARRIER DYNAMICS IN THE PULMONARY CIRCULATION: Hsp90 Inhibition Suppresses Bacterial Endotoxin-Mediated Nf-[kappa] b Transcriptional Activation …
394. Abstract B140: Positron emission tomography imaging of HER2 expression and pharmacodynamic response to Hsp90 inhibition with the next-generation ZHER2 …
395. Inhibition of heat-shock protein 90 (Hsp90) disrupts mutliple pro-angiogenic signaling pathways in gastric cancers cells in vitro and reduces tumor growth and …
396. Hsp90 Inhibition Abrogates the Topoisomerase I Poison-induced G2/M Checkpoint in p53-null Tumor cells by Depleting Chk1 and Wee1
397. Heat Shock Protein 90 (Hsp90) Inhibition as a Potential Novel Approach to the Treatment of Patients with ALK Mutated Non-small Cell Lung Cancer (NSCLC)
398. MP64-14 TARGETING HEAT SHOCK FACTOR 1 SENSITIZES CASTRATION-RESISTANT PROSTATE CANCER CELLS TO Hsp90 INHIBITION IN PART BY …
399. … mutation of PI3K p110alpha subunit in HER2-overexpressing mammary epithelial cells confers a”” stem-like”” phenotype and acute sensitivity to Hsp90 inhibition
400. Heat shock protein 90 (Hsp90) inhibition in squamous cell carcinoma of the head and neck (SCCHN): An in vitro analysis with a focus on p16 status.
401. Inhibition of Hsp90 by AT13387 Delays the Emergence of
402. Acetylation of Hsp90 reverses dexamethasone-mediated inhibition of insulin secretion
403. Local Inhibition of Hsp90 to Prevent Intimal Hyperplasia after Balloon Injury
404. Combination of Hsp90 and mTOR inhibition promotes pancreatic cancer growth inhibition
405. Hsp90 characterization and inhibition: a multi-methodological study
406. Immune Expression and Inhibition of Hsp90 in Retinoblastoma
407. Immune Expression and Inhibition of Hsp90 in Metastatic Uveal Melanoma
408. Therapeutic advantages of inhibition of Hsp90 and proteasomal inhibition in prostate cancer cells
409. Immune expression and inhibition of Hsp90 in uveal melanoma
410. Synthesis of Novel Hsp90 Inhibotor and Its Inhibition
411. Immune Expression and Inhibition of Hsp90 in Human Uveal Melanoma
412. Reduction of cardiac TGFβ-mediated profibrotic events by inhibition of Hsp90 with engineered protein
413. Inhibition of Hsp90 induces BRCA1 degradation and hypersensitivity to ionizing radiation
414. Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of Hsp90 family proteins
415. Therapeutic Inhibition Of Hsp90 Attenuates Fibroblast Activation Involved In Severe Fibrotic Lung Disease
416. Inhibition of curcumin derivative C1209 on proliferation of CML cells by disrupting Hsp90 chaperon function
417. Low-level inhibition of Hsp90 forces cells to tip their (antigenic) hand
418. Induction of enhanced tumor-specific immunity by Hsp90 targeted photodynamic therapy (Hsp90-PDT) combined with immune checkpoint inhibition
419. Inhibition of Hsp90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells
420. Combinatorial inhibition of mTORC2 and Hsp90 leads to a distinctly effective therapeutic strategy in malignant pheochromocytom.
421. Abstract B99: Targeting TPR cochaperones of the Hsp90 molecular chaperone complex for specific inhibition.
422. The stress protein response transiently inhibits STAT1 signaling via inhibition of Hsp90 binding
423. Inhibition of Hsp90 sensitizes pancreatic cancer in vitro and in vivo to chemo-radiotherapy
424. Targeted blockade of Hsp90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition
425. HSP70/Hsp90 Expression in CA9-22 after thermotherapy and the effect of inhibition of HSP70/Hsp90 expression on the efficacy of thermotherapy
426. INHIBITION OF Hsp90 IN TRYPANOSOMA BRUCEI AND PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS OF ANTITRYPANOSOMALS
427. Inhibition of Hsp90 chaperone and 26S proteasomal activities by efrapeptins in breast cancer cells
428. Functional inhibition of Hsp90 induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer
429. Inhibition of heat shock protein 90 (Hsp90) by diterpenoids from roots of Zhumeria majdae
430. C76 HEAT SHOCK PROTEIN: Therapeutic Inhibition Of Hsp90 Attenuates Fibroblast Activation Involved In Severe Fibrotic Lung Disease
431. Inhibition of novobiocin on proliferation of HL-60/Bcr-Abl cells involves disruption of Hsp90 chaperon function
432. 292 INHIBITION OF Hsp90 AGGRAVATES THE EFFECTS OF HEAT SHOCK ON DEVELOPMENTAL COMPETENCE OF BOVINE OOCYTES
433. V599E B-Raf as the next Hsp90 client protein: A novel strategy for selective inhibition of mutated B-Raf
434. Inhibition of Hsp90 enhances T cell-mediated antitumor immune responses through expression of interferon-alpha response Genes
435. Hsp90 protects LPS induced pancreatic inflammation of AR42J cells by inhibition of p38MAPK/NF-κB pathways
436. Inhibition of Hsp90 with NVP-AUY922 induces a synergistic effect in HER2-amplified, trastuzumab-resistant breast and gastric cancer
437. Inhibition of histone deacetylases 1 and 2 increases p21CIP1/WAF1 expression independent of p53 and Hsp90 in colon cancer cells
438. Inhibition of Hsp90 and its Client Kinase FAK has Therapeutic Potential in Squamous Cell Carcinomas of the Uterine Cervix and Oral Cavity
439. In vitro and in vivo inhibition of the Hsp90 molecular chaperone by novel, synthetic, potent pyrazole/isoxazole resorcinol 5-amide analogs
440. Combined Pharmacological Inhibition of Cyclophilins, FK506-Binding Proteins, Hsp90, and Hsp70 Protects Cells From Clostridium botulinum C2 Toxin
441. Inhibition of Hepatitis C Replication by Targeting the Molecular Chaperone Hsp90: Synthesis and Biological Evaluation of 4,5,6,7‐Tetrahydrobenzo[1,2‐d]thiazole …
442. Benzo [a] pyrene Inhibition of Follicular Development and Survival Is Associated with Dysregulation of Hsp90, Bax, CYP1A1, and CYP1B1 Expression.
443. Inhibition of heat stress-related apoptosis of chicken myocardial cells through inducing Hsp90 expression by aspirin administration in vivo
444. Abstract NT-094: TARGETED INHIBITION OF Hsp90 IMPAIRS DNA-DAMAGE RESPONSE PROTEINS AND INCREASES THE SENSITIVITY OF OVARIAN …
445. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/Hsp90 signaling axis
446. Inhibition of heat shock protein 90 (Hsp90) sensitizes HER2-negative breast cancer derived MDA-MD-231 cell line to the cytotoxic effect of troglitazone (TRO)
447. Effects of Hsp90 inhibition on galectin3 expression in human monocytic cell line THP1
448. Radiosensitization of human tumor cells by Hsp90 inhibition
449. Hsp90 inhibition as a way to treat cancer
450. Hsp90 inhibition causes heterochronies in the skull ossification sequences of Pleurodeles waltl (Urodela). Evolutionary implications.
451. Hsp90 Inhibition verbessert die antitumor Effektivität von Rapamycin durch Blockade von Akt und NF-κB
452. Inhibition von Hsp90 in Gemcitabine-und 5-Fluorouracil-resistenten Pankreaskarzinomen
453. Inhibition of Hsp90 with pochoximes: structure-activity relationship and structure-based insights
454. Inhibition von Heat-shock Protein 90 ( Hsp90 ) mittels EC154, einem neuen synthetischen Hsp90 Antagonist, reduziert das Wachstum von humanen Magen-und…
455. VII. Molekulare Onkologie: Therapie Inhibition von Heat-shock Protein 90 ( Hsp90 ) mittels EC154, einem neuen synthetischen Hsp90 Antagonist, reduziert das…
456. Design and synthesis of a library of cyclopeptides and Shepherdine analogues for the inhibition of the Hsp90 -Survivine interaction
457. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitorshttps://www.nature.com/articles/nature01913
458. Hsp90 inhibitors as novel cancer chemotherapeutic agents
459. Hsp90 molecular chaperone inhibitors: are we there yet?
460. Development and application of Hsp90 inhibitors
461. Targeting Hsp90: small-molecule inhibitors and their clinical development
462. Inhibitors of the Hsp90 molecular chaperone: current status
463. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function
464. Update on Hsp90 inhibitors in clinical trial
465. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
466. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket
467. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
468. Hsp90 inhibitors in the clinic
469. Discovery and development of pyrazole-scaffold Hsp90 inhibitors
470. Hsp90 inhibitors identified from a library of novobiocin analogues
471. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
472. The stress response: implications for the clinical development of Hsp90 inhibitors
473. Natural product origins of Hsp90 inhibitors
474. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive
475. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy
476. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation
477. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design
478. Development of purine-scaffold small molecule inhibitors of Hsp90
479. Hsp90 inhibitors reduce influenza virus replication in cell culture
480. Hsp90 inhibitors: current development and potential in cancer therapy
481. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3, 4-diarylpyrazole class of Hsp90 inhibitors
482. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors
483. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice
484. Genetic resistance to JAK2 enzymatic inhibitors is overcome by Hsp90 inhibition
485. Recent advances in Hsp90 inhibitors as antitumor agents
486. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential
487. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors
488. Structure-based discovery of a new class of Hsp90 inhibitors
489. Effectiveness of Hsp90 inhibitors as anti-cancer drugs
490. Maximizing the therapeutic potential of Hsp90 inhibitors
491. Purine-scaffold Hsp90 inhibitors
492. Hsp90 inhibition accelerates cell lysis anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide-and Hsp90-dependent …
493. Emerging Hsp90 inhibitors: from discovery to clinic.
494. Discovery and design of novel Hsp90 inhibitors using multiple fragment‐based design strategies
495. A fluorescence polarization assay for inhibitors of Hsp90
496. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2
497. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification
498. Auditing the Pharmacological Accounts for Hsp90 Molecular Chaperone Inhibitors: Unfolding the Relationship between Pharmacokinetics and Pharmacodynamics1
499. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs
500. Discovery and development of purine-scaffold Hsp90 inhibitors
501. Brain-permeable small-molecule inhibitors of Hsp90 prevent α-synuclein oligomer formation and rescue α-synuclein-induced toxicity
502. Design, synthesis, and biological evaluation of Hsp90 inhibitors based on conformational analysis of radicicol and its analogues
503. Identification of Hsp90 inhibitors as a novel class of senolytics
504. Inhibitors of Hsp90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
505. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer
506. Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors
507. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to Hsp90 inhibitors
508. Fragment‐based identification of Hsp90 inhibitors
509. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential Hsp90 inhibitors
510. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors
511. 3-(5-Chloro-2, 4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone
512. Inhibitors of Hsp90 and other chaperones for the treatment of cancer
513. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 Nterminal ATP binding site
514. High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase
515. Insights into designing the dual-targeted HER2/Hsp90 inhibitors
516. Hsp90 inhibitors as promising agents for radiotherapy
517. p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity
518. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues
519. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors
520. Inhibitors of the Hsp90 molecular chaperone: attacking the master regulator in cancer
521. Adenine derived inhibitors of the molecular chaperone HSP90—SAR explained through multiple X-ray structures
522. Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors
523. Identification of new biomarkers for clinical trials of Hsp90 inhibitors
524. Hsp90 inhibitors for cancer therapy and overcoming drug resistance
525. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to Hsp90 inhibitors
526. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells
527. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development
528. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors
529. Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line
530. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening
531. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90
532. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors: Miniperspective
533. Hsp90 inhibitors in breast cancer: a systematic review
534. Hsp90 inhibitors deplete key anti‐apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin
535. Natural product inhibitors of Hsp90: potential leads for drug discovery
536. Purine-scaffold Hsp90 inhibitors.
537. Medicinal chemistry of Hsp90 inhibitors
538. Hsp90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy
539. Synthesis and evaluation of Hsp90 inhibitors that contain the 1, 4-naphthoquinone scaffold
540. Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran …
541. Geldanamycin and its derivatives as Hsp90 inhibitors
542. High-throughput screening for Hsp90 ATPase inhibitors
543. Preclinical characterization of mitochondria-targeted small molecule Hsp90 inhibitors, gamitrinibs, in advanced prostate cancer
544. Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma
545. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone
546. Development of a high throughput drug screening assay for the detection of changes in tau levels-proof of concept with Hsp90 inhibitors
547. Targeting the Hsp90 chaperone: synthesis of novel resorcylic acid macrolactone inhibitors of Hsp90
548. Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (Hsp90) molecular chaperone
549. Structure‐based and in silico design of Hsp90 inhibitors
550. Hsp90 and its inhibitors
551. Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors
552. Novel Hsp90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair …
553. Natural Product Inspired N‐Terminal Hsp90 Inhibitors: From Bench to Bedside?
554. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines
555. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer‐initiating cells
556. Genes and proteins governing the cellular sensitivity to Hsp90 inhibitors: a mechanistic perspective
557. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy.
558. Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives
559. Targeting of KRAS mutant tumors by Hsp90 inhibitors involves degradation of STK33
560. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors
561. Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism
562. Constitutively-active androgen receptor variants function independently of the Hsp90 chaperone but do not confer resistance to Hsp90 inhibitors
563. An AlphaScreenTM-Based High-Throughput Screen to Identify Inhibitors of Hsp90-Cochaperone Interaction
564. Assays for Hsp90 and inhibitors
565. N-Aryl-benzimidazolones as novel small molecule Hsp90 inhibitors
566. Molecular basis for the actions of Hsp90 inhibitors and cancer therapy
567. Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus
568. Synthesis of pochoxime prodrugs as potent Hsp90 inhibitors
569. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells
570. Inside the Hsp90 inhibitors binding mode through induced fit docking
571. … 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90β, a property that can be exploited in screens for new Hsp90 chaperone inhibitors
572. Learning from nature: advances in geldanamycin-and radicicol-based inhibitors of Hsp90
573. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (Hsp90) inhibitors targeting proliferation and angiogenesis
574. Hsp90 inhibitors and drugs from fragment and virtual screening
575. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression
576. Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax
577. … of Hsp90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
578. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway
579. Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series
580. A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors
581. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors
582. Anticancer inhibitors of Hsp90 function: beyond the usual suspects
583. Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors
584. Hsp90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors
585. Inhibition of Hsp90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma …
586. Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 …
587. Tricyclic Series of Heat Shock Protein 90 (Hsp90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-c]pyridines as Potent Inhibitors of the Hsp90 Molecular …
588. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors
589. A Chemical–Biological Study Reveals C9-type Iridoids as Novel Heat Shock Protein 90 (Hsp90) Inhibitors
590. Exploring the binding site of C-terminal Hsp90 inhibitors
591. 5-Aryl-4-(5-substituted-2, 4-dihydroxyphenyl)-1, 2, 3-thiadiazoles as inhibitors of Hsp90 chaperone
592. Organelle-specific Hsp90 inhibitors
593. Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells
594. Hsp90 inhibitors as therapy for multiple myeloma
595. Isoxazolo (aza) naphthoquinones: A new class of cytotoxic Hsp90 inhibitors
596. Combining trail with PI3 kinase or Hsp90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling
597. Hsp90 inhibitors as new leads to target parasitic diarrheal diseases
598. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone
599. Impact of posttranslational modifications on the anticancer activity of Hsp90 inhibitors
600. Mps1 mediated phosphorylation of Hsp90 confers renal cell carcinoma sensitivity and selectivity to Hsp90 inhibitors
601. Synthesis and evaluation of new Hsp90 inhibitors based on a 1, 4, 5-trisubstituted 1, 2, 3-triazole scaffold
602. Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/Hsp90 dual-targeted inhibitors
603. Hsp90 inhibitors in lung cancer: promise still unfulfilled
604. Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux
605. Paralog specific Hsp90 inhibitors–a brief history and a bright future
606. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors
607. Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
608. Structural determination of three different series of compounds as Hsp90 inhibitors using 3D-QSAR modeling, molecular docking and molecular dynamics …
609. Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity
610. Development of heat shock protein (Hsp90) inhibitors to combat resistance to tyrosine kinase inhibitors through HSP90–kinase interactions
611. Potent antitumor activity of the novel Hsp90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
612. Discovery of potent N-(isoxazol-5-yl) amides as Hsp90 inhibitors
613. Design, Synthesis, and Biological Evaluation of Conformationally Constrained cis-Amide Hsp90 Inhibitors
614. IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma
615. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and Hsp90 inhibitors
616. Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as Hsp90 C-terminal inhibitors
617. … Conformational Dynamics between Plasmodium falciparum and Human Hsp90 Orthologues Enable the Structure-Based Discovery of Pathogen-Selective Inhibitors
618. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for Hsp90 inhibitors
619. Principal component analysis on molecular descriptors as an alternative point of view in the search of new Hsp90 inhibitors
620. Reversing drug resistance of cisplatin by Hsp90 inhibitors in human ovarian cancer cells
621. Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as …
622. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors
623. Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for …
624. FBW7-dependent Mcl-1 degradation mediates the anticancer effect of Hsp90 inhibitors
625. Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): synthesis, biology, and molecular modeling
626. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity
627. Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy
628. Hsp90 inhibitors attenuate effect of dexamethasone on activated NF-κB and AP-1
629. Possible effects of early treatments of Hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs
630. Synthesis and biological evaluation of novobiocin core analogues as Hsp90 inhibitors
631. Heat shock protein 90 (Hsp90) inhibitors activate the heat shock factor 1 (HSF1) stress response pathway and improve glucose regulation in diabetic mice
632. Synthesis and antiproliferative activity of novobiocin analogues as potential Hsp90 inhibitors
633. High-throughput screen of natural product libraries for Hsp90 inhibitors
634. Hsp90 inhibitors NVP-AUY922 and NVP-BEP800 may exert a significant radiosensitization on tumor cells along with a cell type-specific cytotoxicity
635. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss
636. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors
637. Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo [2, 3-d] pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based …
638. Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells
639. Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel Hsp90 inhibitors
640. Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action
641. A potential role for Hsp90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry
642. Development of noviomimetics as C-terminal Hsp90 inhibitors
643. A large animal model to evaluate the effects of Hsp90 inhibitors for the treatment of lung adenocarcinoma
644. Solution-phase parallel synthesis of Hsp90 inhibitors
645. Molecular docking study, synthesis and biological evaluation of Schiff bases as Hsp90 inhibitors
646. 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer
647. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors
648. Use of Hsp90 inhibitors to disrupt GDI‐dependent Rab recycling
649. … -mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1α destabilization by SH-1242 and SH-1280, novel Hsp90 inhibitors
650. Practical synthesis of novel purine analogues as Hsp90 inhibitors
651. Hsp90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells
652. Novel Hsp90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion
653. Asymmetric synthesis of pochonin E and F, revision of their proposed structure, and their conversion to potent Hsp90 inhibitors
654. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido [4, 3-d] pyrimidines core through shape-based screening
655. Identification of limonol derivatives as heat shock protein 90 (Hsp90) inhibitors through a multidisciplinary approach
656. An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors–potential therapeutics in cancer and neurodegeneration
657. RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells
658. Design and synthesis of 2-amino-6-(1H, 3H-benzo [de] isochromen-6-yl)-1, 3, 5-triazines as novel Hsp90 inhibitors
659. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors
660. Breast cancer and Hsp90 inhibitors: is there a role beyond the HER2-positive subtype?
661. HSP27 knockdown produces synergistic induction of apoptosis by Hsp90 and kinase inhibitors in glioblastoma multiforme
662. Identification of new Hsp90 inhibitors by structure-based virtual screening
663. Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs
664. Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1, 2, 3-thiadiazole Hsp90 inhibitors
665. Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening
666. Identification of a new series of potent diphenol Hsp90 inhibitors by fragment merging and structure-based optimization
667. Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90
668. The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors
669. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors
670. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma
671. Hsp90 inhibitors, part 2: combining ligand-based and structure-based approaches for virtual screening application
672. Client proteins and small molecule inhibitors display distinct binding preferences for constitutive and stress-induced Hsp90 isoforms and their …
673. Hsp90 inhibitors disrupt a transient Hsp90-HSF1 interaction and identify a noncanonical model of Hsp90-mediated HSF1 regulation
674. Hsp90 inhibitors, geldanamycin and radicicol, enhance fisetin-induced cytotoxicity via induction of apoptosis in human colonic cancer cells
675. Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors
676. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis
677. Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors.
678. ER homeostasis and motility of NSCLC cell lines can be therapeutically targeted with combined Hsp90 and HDAC inhibitors
679. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1
680. Synthesis and biological evaluation of 3, 5-disubstituted-4-alkynylisoxozales as a novel class of Hsp90 inhibitors
681. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC)
682. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity
683. Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study
684. Clinical evaluation and biomarker profiling of Hsp90 inhibitors
685. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system
686. How selective are Hsp90 inhibitors for cancer cells over normal cells?
687. … II study of Hsp90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors …
688. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90
689. Redefining the phenotype of heat shock protein 90 (Hsp90) Inhibitors
690. Multiclass comparative virtual screening to identify novel Hsp90 inhibitors: a therapeutic breast cancer drug target
691. 2, 4-dihydroxy benzaldehyde derived Schiff bases as small molecule Hsp90 inhibitors: Rational identification of a new anticancer lead
692. A computational analysis of pyrazole-based inhibitors binding to Hsp90 using molecular dynamics simulation and the MM-GBSA method
693. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis
694. A novel class of small molecule inhibitors of Hsp90
695. 4, 5, 6, 7-Tetrahydro-isoxazolo-[4, 5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors
696. … and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl) phenyl)-arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in …
697. Hsp90 inhibitors for the treatment of chronic myeloid leukemia
698. Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins
699. Virtual screening and biophysical studies lead to Hsp90 inhibitors
700. Hsp90 inhibitors: a potential treatment for latent EBV infection?
701. Biological evaluation of 3-acyl-2-arylamino-1, 4-naphthoquinones as inhibitors of Hsp90 chaperoning function
702. Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular …
703. HDAC and Hsp90 inhibitors down‐regulate PTTG1/securin but do not induce aneuploidy
704. AKT kinase and Hsp90 inhibitors as novel anti-cancer therapeutics
705. Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
706. Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of Hsp90 inhibitors
707. A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes
708. Protection of oligodendrocyte precursor cells by low doses of Hsp90 inhibitors in cell culture
709. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (Hsp90)
710. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90
711. Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors
712. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors
713. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors
714. Ansamycin inhibitors of Hsp90: nature’s prototype for anti-chaperone therapy
715. Design and synthesis of 3′, 5′-ansa-adenosines as potential Hsp90 inhibitors
716. Reinventing Hsp90 Inhibitors: Blocking C‐Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors
717. New dihydropyrimidin-2 (1 H)-one based Hsp90 C-terminal inhibitors
718. Hsp90 inhibitors, part 1: definition of 3-D QSAutogrid/R models as a tool for virtual screening
719. Combined pharmacophore and structure-guided studies to identify diverse Hsp90 inhibitors
720. High cytotoxic sensitivity of the oligodendrocyte precursor cells to Hsp90 inhibitors in cell cultures
721. Hsp90 inhibitors in oncology: ready for prime time?
722. Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo [2, 3-d] pyrimidines as potent Hsp90 inhibitors
723. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors
724. … and pharmacological evaluation of 4, 5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors
725. The non-Geldanamycin Hsp90 inhibitors enhanced the antifungal activity of fluconazole
726. Ligand desolvation steers on-rate and impacts drug residence time of heat shock protein 90 (Hsp90) inhibitors
727. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors
728. Chemoproteomics-driven drug discovery: identification of novel Hsp90 inhibitors
729. Dimeric and trimeric triazole based molecules as a new class of Hsp90 molecular chaperone inhibitors
730. Design, synthesis, and structure activity relationships for chimeric inhibitors of Hsp90
731. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition
732. Macrocyclic inhibitors of hsp90
733. Hsp90 inhibitors decrease AID levels and activity in mice and in human cells
734. Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites
735. Discovery of Novel 17‐Phenylethylaminegeldanamycin Derivatives as Potent Hsp90 Inhibitors
736. Proteolytic degradation of nitric oxide synthase: effect of inhibitors and role of Hsp90-based chaperones
737. Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) Inhibitors
738. A global view of the proteome perturbations by Hsp90 inhibitors
739. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (Hsp90) inhibitors
740. Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors
741. 2′‐O‐Alkyl Derivatives and 5′‐Analogues of 5‐Aminoimidazole‐4‐carboxamide‐1‐β‐D‐ribofuranoside (AICAR) as Potential Hsp90 Inhibitors
742. Effects of Hsp90 inhibitors, geldanamycin and its analog, on ceramide metabolism and cytotoxicity in PC12 cells
743. Structure–activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity
744. Identification of the key structural elements of a dihydropyrimidinone core driving toward more potent Hsp90 C-terminal inhibitors
745. Design, synthesis, and anticancer activity of C8-substituted-4′-thionucleosides as potential Hsp90 inhibitors
746. Discovery of novel Hsp90 inhibitors that induced apoptosis and impaired autophagic flux in A549 lung cancer cells
747. Molecular docking study, synthesis and biological evaluation of Mannich bases as Hsp90 inhibitors
748. Dynamics-based discovery of allosteric inhibitors: Selection of new ligands for the C-terminal domain of Hsp90
749. Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitization
750. Hsp90 inhibitors as senolytic drugs to extend healthy aging
751. Design and synthesis of N-(5-chloro-2, 4-dihydroxybenzoyl)-(R)-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors
752. Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors
753. An Improved Synthesis of Resorcylic Acid Macrolactone Inhibitors of Hsp90
754. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer
755. Hsp90 inhibitors
756. Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold
757. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of Hsp90 and HDAC
758. Potentiation of Topoisomerase I inhibitors by Hsp90 inhibitors: Mechanistic and Functional studies
759. Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not Hsp90 inhibitors in models of HER2 amplified breast cancer
760. Correlation between crystal violet dissolution assay and manual colony counting on the In Vitro effects of Hsp90-inhibitors.
761. Hsp90 inhibitors and the reduction of anti-cancer drug resistance by non-genetic and genetic mechanisms
762. Stability of the human Hsp90-p50Cdc37 chaperone complex against nucleotides and Hsp90 inhibitors, and the influence of phosphorylation by casein kinase 2
763. Design, synthesis and biological evaluation of 7-(aryl)-2, 3-dihydro-[1, 4] dioxino [2, 3-g] quinoline derivatives as potential Hsp90 inhibitors and anticancer agents
764. Discovery of 5-substituted 2-amino-4-chloro-8-((4-methoxy-3, 5-dimethylpyridin-2-yl) methyl)-7, 8-dihydropteridin-6 (5H)-ones as potent and selective Hsp90 inhibitors
765. Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC)
766. Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities
767. Hsp90 inhibitors alter capsaicin-and ATP-induced currents in rat dorsal root ganglion neurons
768. Sensitization of multidrug-resistant cancer cells to Hsp90 inhibitors by NSAIDs-induced apoptotic and autophagic cell death
769. Effects of Hsp90 binding inhibitors on sGC-mediated vascular relaxation
770. Spontaneous assembly of Hsp90 inhibitors at water/octanol interface: A molecular dynamics simulation study
771. Discovery of potent and selective CDK8 inhibitors from an Hsp90 pharmacophore
772. Hsp90 inhibitors radicicol and geldanamycin have opposing effects on Leishmania Aha1-dependent proliferation
773. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors
774. A group of novel HIF‐1α inhibitors, glyceollins, blocks HIF‐1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding
775. Recent advances in macrocyclic Hsp90 inhibitors
776. Identification of Hsp90 inhibitors with anti-Plasmodium activity
777. 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold
778. Computational predictions of corroles as a class of Hsp90 inhibitors
779. Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening
780. Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and Hsp90 inhibition
781. New Indications for Hsp90 and HSP70 Inhibitors as Antiviral Drugs
782. … study of the Hsp90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR …
783. Crystallization and preliminary X-ray diffraction analysis of Trap1 complexed with Hsp90 inhibitors
784. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas …
785. Lead identification: better Hsp90 inhibitors
786. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C‐terminal Inhibitors
787. Triazole containing novobiocin and biphenyl amides as Hsp90 C-terminal inhibitors
788. Recent progress in the study of Hsp90 inhibitors [J]
789. Met amplification and Hsp90 inhibitors
790. A novel pharmacodynamic assay to measure Hsp90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors
791. Synthesis and evaluation of 4-(2-hydroxypropyl) piperazin-1-yl) derivatives as Hsp90 inhibitors
792. Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (Hsp90)
793. Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape‐Based Similarity Screening
794. The Hsp90 Inhibitors, 17-aag and 17-dmag Target Wild-Type B-raf Signaling for the Proliferation of Human Uveal Melanoma Cells
795. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2, 4-diaminopyrimidine motifs
796. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST …
797. Low-dose Hsp90 inhibitors DPB and AUY-922 repress apoptosis in HUVECs
798. Hsp90 inhibitors in parasitic nematodes: prospects and challenges
799. Preface [Hot topic: Hsp90 Molecular Chaperone Inhibitors: Opportunities and Challenges (Guest Editor: Paul Workman)]
800. Combination therapies with Hsp90 inhibitors against colorectal cancer
801. Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases
802. Design and biological testing of peptidic dimerization inhibitors of human Hsp90 that target the C-terminal domain
803. Hsp90 inhibitors suppress P53 phosphorylation in LPS-induced endothelial inflammation
804. Evaluation of miscellaneous heat shock protein (Hsp90) inhibitors using different methodologies
805. Hsp90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line
806. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors
807. Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C‐Terminal Inhibitors
808. Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors
809. Synthesis of 5,6‐dihydro‐4H‐benzo[d]isoxazol‐7‐one and 5,6‐dihydro‐4H‐isoxazolo[5,4‐c]pyridin‐7‐one Derivatives as Potential Hsp90 Inhibitors
810. A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structure–activity relationships and anti-HCV activity in …
811. New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting
812. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors
813. Hsp90 inhibitors potentiate PGF2α-induced IL-6 synthesis via p38 MAP kinase in osteoblasts
814. Combination of jak2 and Hsp90 inhibitors: An effective therapeutic option in drug-resistant chronic myelogenous leukemia
815. Abstract# 1710: A novel pharmacodynamic assay to measure Hsp90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors
816. Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain
817. Study on the Hsp90 Inhibitors
818. Combined in Silico and Experimental Approach for Drug Design: The Binding Mode of Peptidic and Non‐Peptidic Inhibitors to Hsp90 N‐Terminal Domain
819. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors
820. Hsp90 inhibitors are promising radiosensitizers for radiotherapy
821. Synthesis and biological evaluation of hybrid acridine-Hsp90 ligand conjugates as telomerase inhibitors
822. … vitro study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble Hsp90 inhibitor, 17-AAG …
823. Inhibitors of the Hsp90 C-terminus
824. The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and …
825. Reduction of benzoquinone ansamycin Hsp90 inhibitors by NQO1 generates hydroquinone ansamycins which are more potent Hsp90 inhibitors
826. Investigation of B, C-ring truncated deguelin derivatives as heat shock protein 90 (Hsp90) inhibitors for use as anti-breast cancer agents
827. Identifying inhibitors of the Hsp90-Aha1 protein complex, a potential target to drug cystic fibrosis, by alpha technology
828. Combining ensemble learning with a fragment-based topological approach to generate new molecular diversity in drug discovery: In silico design of Hsp90 inhibitors
829. Design, synthesis, and biological activities of vibsanin B derivatives: a new class of Hsp90 C-terminal inhibitors
830. Progress in the study of small molecule inhibitors of HSP90
831. Virtual Screening for Dual Hsp90/B-Raf Inhibitors
832. Prediction of inhibitory activities of Hsp90 inhibitors
833. New Hsp90 selective inhibitors as therapeutic agents for prostate and bladder cancer.
834. 145 POSTER Hsp90 inhibitors target addiction to mutant oncoproteins in colorectal cancer
835. 570 POSTER Overcoming resistance to tyrosine kinase inhibitors (TKls) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets …
836. Towards ‘best-in-class’ Hsp90 inhibitors: Design, biosynthesis and pre-clinical profiles
837. Evaluation of the effect of Hsp90 inhibitors on head and neck squamous cell carcinoma cell lines
838. Mechanism of action of a novel series of inhibitors of the Hsp90 molecular chaperone
839. Effects of Inhibitors on Hsp90′ s Conformational Dynamics, Cochaperone and Client Interactions
840. Design and synthesis of imidazopyridine derivatives as novel Hsp90 inhibitors for the treatment of cancer
841. Therapeutic Uses of Hsp90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)
842. Development of a FRET-based high-throughput screening system for the discovery of Hsp90 inhibitors
843. Histone deacetylase inhibitors interrupt HSP90• RASGRP1 and HSP90• CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells
844. Inhibition of mTOR enhances the activity of Hsp90 inhibitors in part through cessation of heat shock protein synthesis.
845. Hsp90 Flexibility and Development of its Inhibitors for the Treatment of Cancer
846. Neuroprotective Features Of Hsp90 Inhibitors Exhibiting Anti-Inflammatory Actions: Implications For Multiple Sclerosis
847. Integration of Hsp90 inhibitors in combinational immunotherapy targeting receptor tyrosine kinases (RTKs) in cancer (131.45)
848. Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells
849. … the in-silico design of new Hsp90 inhibitors: Molecular docking and 3D-QSAR CoMFA studies of tetrahydropyrido [4, 3-d] pyrimidine derivatives as Hsp90 inhibitors
850. Hsp90 inhibitors stimulate DNAJB4 protein expression through a mechanism involving N 6-methyladenosine
851. Hsp90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways
852. Structural and energetic insight into the isoform-selective inhibitors of tumour marker Hsp90 against Grp94
853. In vitro and in vivo Evaluation of 17-phenylpropylamine/phenoxyethylamine-17-demethoxygeldanamycins as Potent Hsp90 Inhibitors
854. Suppression by Hsp90 inhibitors of BMP‑4‑stimulated osteoprotegerin synthesis in osteoblasts: Attenuation of p70 S6 kinase
855. Synthesis and evaluation of the tumor cell growth inhibitory potential of new putative Hsp90 inhibitors
856. Drug metabolism determines resistance of colorectal cancer to resorcinol-based Hsp90 inhibitors
857. The importance of dose schedule with Hsp90 inhibitors: Results from a Phase II study in dogs with mast cell tumors.
858. Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants
859. New heat shock protein (Hsp90) inhibitors, designed by pharmacophore modeling and virtual screening: synthesis, biological evaluation and molecular dynamics …
860. C-Terminal Hsp90 Inhibitors Block the HIF-1 Hypoxic Response by Degrading HIF-1α through the Oxygen-Dependent Degradation Pathway
861. Prediction of new Hsp90 inhibitors based on 3, 4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation
862. A potential role for NAD (P) H: quinone oxidoreductase 1 (NQO1) in the mechanism of action of the Hsp90 inhibitors geldanamycin and 17AAG
863. Dorsomorphin induces cancer cell apoptosis and sensitizes cancer cells to Hsp90 and proteasome inhibitors by reducing nuclear heat shock factor 1 levels
864. Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor …
865. Correction: Identification of the key structural elements of a dihydropyrimidinone core driving toward more potent Hsp90 C-terminal inhibitors
866. … and pharmacological evaluation of N-(5-chloro-2, 4-dihydroxybenzoyl)-(R)-N-arylmethyl-1, 2, 3, 4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors
867. Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain
868. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors
869. Overcoming Resistance to Small Molecule Kinase Inhibitors (SMKIs) Through Inhibition of Heat Shock Protein 90 (Hsp90) Chaperone Function in Patients with …
870. Investigation of the Hsp90 C-terminal binding site, novel inhibitors and isoform-dependent client proteins
871. Hsp90 inhibitors and conjunctival melanoma
872. Potentials of Hsp90 Inhibitors in Cancer Therapy. pdf
873. Development of Novel Inhibitors of HSP90
874. Natural product inspired Hsp90 inhibitors
875. A New Generation of Isoform Selective Hsp90 Inhibitors: Targeting the Cytosolic Hsp90 Isoforms
876. Circumventing Hsp90 inhibitors via apoptosis block
877. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors
878. QS288. Potent Blockade of TGF-β Signaling by Hsp90 Inhibitors
879. Hsp90 inhibitors for high-grade glioma treatment
880. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
881. The role of NQO1 in the metabolism of benzoquinone ansamycin Hsp90 inhibitors and development of novel Hsp90 inhibitors as anticancer agents
882. Structure-based drug discovery of species-selective inhibitors of Hsp90
883. Potent non-benzoquinone ansamycin Hsp90 inhibitors from mutasynthesis
884. Targeting oncogenic Eph receptor proteins with Hsp90 inhibitors
885. Client depletion assay comparison of paclitaxel to Hsp90 inhibitors
886. Hsp90 Inhibitors in Sepsis and Sepsis-induced Acute Lung Injury
887. 19-Substituted benzoquinone ansamycin Hsp90 inhibitors: Effects on Hsp90 co-chaperones and Hsp90-Hsf1 complexes in cellular systems
888. In Vitro Dual Treatment of Cancer Cells with Hsp90 Inhibitors and Hyperthermia
889. Recent Advances in the Discovery of Novel Hsp90 Inhibitors: An Update from 2014.
890. Abstract# 3697: Combination of Hsp90 inhibitors and MEK inhibitors abrogates ERK activation in pancreatic cancer cells
891. Targeting basal-like breast cancer via purine-scaffold Hsp90 inhibitors
892. C-terminal Hsp90-inhibitors restore glucocorticoid sensitivity in Cushing’s disease
893. Development of Hsp90 paralog specific inhibitors with mitochondrial drug delivery system
894. Use of Hsp90 inhibitors in the combination immunotherapy of melanoma (P4272)
895. Abstract# 915: Cystine/glutamate transporter SLC7A11 mediates resistance to Hsp90 inhibitors
896. Proteomic Profiling of Hsp90 Inhibitors
897. Synthetic Hsp90 inhibitors are active against 17-AAG-resistant tumor lines
898. Acquired resistance to Hsp90-inhibitors and cancer progression
899. Profiling Hsp90 inhibitors in cellular extracts on a mass spectrometry chemoproteomics platform
900. 19-Substituted benzoquinone ansamycins. Hsp90 inhibitors with decreased off-target toxicity
901. Barrier-protective effects of Hsp90 inhibitors in bovine pulmonary arterial endothelial cells.
902. Hsp90 Inhibitors in Clinic
903. Synthesis and exploration of resorcinol derivatives as Plasmodium falciparum Hsp90 inhibitors
904. Inhibitors of Hsp90 in melanoma
905. Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity
906. Verification of a multivariate pharmacodynamic biomarker assay for Hsp90 inhibitors
907. MP05-16 TSC1 EXPRESSION AS A PREDICTIVE BIOMARKER OF BLADDER CANCER RESPONSE TO Hsp90 INHIBITORS
908. Computational modeling of the Hsp90 interactions with cochaperones and Small-Molecule inhibitors
909. Hsp90 inhibitors: Biosynthetic and antitumor evaluation of a non-geldanamycin polyketide
910. Hsp90 Inhibitors as New Leads To Target
911. Development of a multivariate pharmacodynamic biomarker assay for Hsp90 inhibitors
912. Abstract C86: Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.
913. Correlation between in vitro and in vivo activities of Hsp90 inhibitors
914. Hsp90 inhibitors target KRAS mutant human tumors through degradation of STK33
915. Application of Hsp90 inhibitors to treat chronic lymphocytic leukemia by targeting the BCR-NFκB pathway
916. Effect of 19-substituted benzoquinone ansamycin Hsp90 inhibitors on Hsp90/Cdc37/co-chaperone complexes and casein kinase 2 (CK2) activity
917. Discovery of novel small molecule inhibitors of Hsp90 for oral treatment
918. Synergistic inhibition of cancer cell viability and suppression of HIF1α by CDK4 inhibitors and Hsp90 inhibitors across cancer types
919. Silencing of the heat shock protein 90 (Hsp90) cochaperone CDC37 by RNA interference sensitises cancer cells to Hsp90 inhibitors
920. Discovery of N‐pyridoyl‐Δ2‐pyrazolines as Hsp90 inhibitors
921. Hsp90 inhibitors as a future therapeutic strategy in diabetes-driven atherosclerosis.
922. 555 POSTER Small-molecule inhibitors of Hsp90 in IM-resistant gastrointestinal stromal tumors
923. Anti-tumor activity of non-benzoquinone ansamycin Hsp90 inhibitors in murine xenograft models
924. C-terminal Hsp90 inhibitors restore glucocorticoid sensitivity in an experimental model for Cushing’s disease
925. Abstract B36: Targeting BRCA1 through natural Hsp90 inhibitors to reverse platinum resistance in TNBC
926. Efficacy of the Hsp90 Inhibitors in Prostate Cancer Therapy
927. Potent anti-inflammatory activity of a novel of class Hsp90 inhibitors for multiple sclerosis (51.1)
928. Potential of Hsp90 Inhibitors to Treat Neurofibromatosis-Related Tumors
929. Screening of miscellaneous Hsp90 inhibitors using virtual co-crystallized pharmacophore
930. Design, synthesis and biological evaluation of ansamycin prodrugs as water-soluble Hsp90 inhibitors
931. Role of Hsp90 Inhibitors in the Treatment of Cancer
932. A high-throughput screen for inhibitors of the Hsp90-chaperone machine
933. Small-molecule Hsp90 Inhibitors: Applications in Cancer and Neurodegenerative diseases
934. Anti-cancer effect by combination treatment of CDK and Hsp90 inhibitors through HIF1α inhibition
935. C-terminal Hsp90 Inhibitors Block the HSP90: HIF-1a Interaction and Inhibit the Cellular Hypoxic Response
936. p23/Sba1p protects against Hsp90 inhibitors
937. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression
938. PHARMACOPHORIC MODEL AND 3D-QSAR OF 5-RESORCINOL-ISOXAZOLE DERIVATIVES AS Hsp90 INHIBITORS
939. Abstract# 4688: Hsp90 inhibitors downregulate the VEGF excretion in triple negative breast cancer cells
940. Rational Identification of Hsp90 Inhibitors as Anticancer Lead Molecules by Structure Based Drug Designing Approach.
941. P2-384: In vivo effects of novel Hsp90 C-terminal inhibitors in Tau mutant mice
942. In vivo antitumor efficacy of purine-scaffold Hsp90 inhibitors in basal-like breast cancer (BLBC)
943. 19P Comparative effectiveness analysis of Hsp90 inhibitors in non-small cell lung cancer
944. Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by Hsp90 inhibitors
945. The Potential Dual-Target Inhibitors for HER2/Hsp90 Proteins from Traditional Chinese Medicine
946. Development of a cell-based ligand-screening system for identifying Hsp90 inhibitors
947. Precursor-directed biosynthesis of macbecin analogues: generation of non-quinone containing Hsp90 inhibitors and pre-clinical evaluation
948. Selective inhibition of Hsp90 by its C-terminal inhibitors is more effective to suppress bladder cancer cell growth
949. Hsp90 inhibitors prevent LPS-induced endothelial barrier dysfunction by disrupting RhoA signaling.
950. Hsp90 inhibitors prevent LPS-induced endothelial hyper-permeability by inhibiting pp60src activation and maintaining adherens junction proteins
951. Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures
952. Discovery of Hsp90 Inhibitors from Natural Product and Its Analogues
953. Effects of Hsp90 inhibitors on triple-negative breast cancer: BRCA1 as a therapeutic target for TNBC
954. AB035. P006. Activity of heat shock protein-90 (Hsp90) inhibitors against pancreatic cancers grown in 3 dimensions
955. Cover Feature: Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C‐Terminal Inhibitors (ChemMedChem 24/2017)
956. Combination use of natural Hsp90 inhibitors to reverse BRCA1-mediated platinum resistance in triple negative breast cancer
957. Hsp90 inhibitors induce the unfolded protein response in bovine and mice lung cells
958. A detailed analysis of protein binding and biological activity of methoxy-substituted resorcinylic isoxazole amide Hsp90 inhibitors
959. Fe3O4 nanoparticles mediated synthesis of novel spirooxindole‐dihydropyrimidinone molecules as Hsp90 inhibitors
960. A genome-wide CRISPR/Cas9 pooled screen identifies EML4-ALK variant-specific synthetic lethal partners of Hsp90 inhibitors
961. Discovery of Heat Shock Protein 90 (Hsp90) Inhibitors against Cancerous Diseases
962. Cell cycle control and apoptosis of p53-isogenic cell lines treated with Hsp90 inhibitors
963. Novel Hsp90 inhibitors exhibiting in vivo xenograft activity discovered using fragment-based drug discovery & structure based drug design.
964. Targeting Hsp90 with small molecule inhibitors induces the overexpression of the anti-apoptotic molecule, survivin, in human cancer cells
965. Discovery of Novel Hsp90 Inhibitors and Evaluation of Their Antitumor Activities
966. Differential sensitivities to heat shock protein 90 (Hsp90) inhibitors in anaplastic lymphoma kinase (ALK)-positive non-small cell ling cancer (NSCLC) cells.
967. Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors
968. Design, Synthesis, and Evaluation of Site-Specific Hsp90 Inhibitors
969. Abstract B102: 19-Substituted benzoquinone ansamycins: Decreasing the toxicity of the benzoquinone ansamycin class of Hsp90 inhibitors.
970. Real-time imaging of disruption of human heat shock protein 90/co-chaperone p23 interactions by Hsp90 inhibitors in living subjects
971. Hsp90 Inhibitors Blocking Multiple Oncogenic Signaling Pathways for the Treatment of Cancer
972. Development of Hsp90 Inhibitors for the Treatment of HER-2 Positive Solid Cancers
973. Discovery of Hsp90 inhibitors form natural product and its analogues
974. Rational synthesis and evaluation of IMP dehydrogenase and Hsp90 inhibitors
975. Abstract# 4677: NVP-BEP795 and NVP-BEP800: Novel, fragment derived orally bioavailable small molecule Hsp90 inhibitors with potent antitumor activity
976. Ansamycin Class of Natural Product Hsp90 Inhibitors
977. Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies
978. … OF Hsp90 SUBPOPULATION CONFORMATIONS TARGETED BY INHIBITORS AND THE EFFECT OF PHOSPHORYLATION ON HSP90’S ASSOCIATION WITH CO …
979. HSP70 and Hsp90 Inhibitors Repress Expression of TSC1 in T24 Bladder Cancer Cells and UOK139, UOK 140 Kidney Cancer Cells
980. Identification of the correlation between drug activity and sensitivity of Hsp90 inhibitors in breast cancer cells using a multivariate gene expression assay
981. Proteomic Analysis of Hct116 Colon Cancer Cells Treated with Inhibitors That Bind to the N-terminal Versus the C-terminal Domain of Hsp90
982. Differential Sensitivities of Human Multidrug-resistant Cancer Cells to BIIB021 and Modulation of Hsp90 Inhibitors by NSAIDs and Niclosamide
983. Design of Novel Hsp90 Inhibitors to Trigger Tau Degradation in Alzheimer’s disease: An Insilico Approach
984. Assessing efficacy of novel Hsp90 inhibitors in breast cancer patients by enumeration of circulating tumor cells and HER-2 degradation
985. Hsp90 inhibitors diminish PDGF-BB-induced migration of osteoblasts via suppression of p44/p42 MAP kinase
986. Identification and Structure-Activity Studies of 1, 3-Dibenzyl-2-aryl imidazolidines as Novel Hsp90 Inhibitors
987. Design, synthesis, and molecular docking studies of novel pyrazolyl 2‐aminopyrimidine derivatives as Hsp90 inhibitors
988. 281P Selective depletion of tumour-associated SAMHD1 by Hsp90 inhibitors enhances the anti-AML effect of cytarabine
989. Insights into the molecular mechanism of Hsp90 binding of methoxy-substituted resorcinylic isoxazole amide inhibitors reveal different isoform selectivity profiles
990. Hch1p Acts Differently From Its Homologue, Aha1p, in Regulating Sensitivity of Hsp90 to Hsp90 Inhibitors in Yeast
991. Ddis-12. Cyto-mito™-A Novel Class Of Dual-acting Hsp90 Inhibitors For The Treatment Of Glioblastoma
992. Hsp90 inhibitors: their effects on redox status and on the cytoarchitecture
993. Trth-03. Cyto-mito™-A Novel Class Of Dual-acting Hsp90 Inhibitors For The Treatment Of Glioblastoma
994. Development of Tethered Hsp90 Inhibitors Carrying Radioiodinated Probes to Specifically Discriminate and Kill Malignant Breast Tumor Cells
995. Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and Hsp90 Inhibitors
996. Abstract PR05: Effects of Hsp90 inhibitors on triple-negative breast cancer: Notch as a therapeutic target for stem cells
997. Reduction of a series of benzoquinone ansamycin Hsp90 inhibitors by one and two electron reductases, and their interaction with reduced glutathione
998. Design and synthesis of fungal-selective resorcylate aminopyrazole Hsp90 inhibitors
999. Abstract B018: A high-throughput screen identifies Hsp90 inhibitors as potent therapeutics across multiple clinically representative organoid models of advanced …
1000. Hsp90 Inhibitors Suppress Aryl Hydrocarbon Receptor-Mediated Activation of CYP1A1 and CYP1B1 Transcription and DNA Adduct Formation
1001. Medium-Throughput Detection of Hsp90/Cdc37 Protein–Protein Interaction Inhibitors Using a Split Renilla Luciferase-Based Assay
1002. Decoupling the mechanism of action of efrapeptins, dual inhibitors of proteasome and Hsp90 chaperone function: The possible role of endoplasmic reticulum stress
1003. Structure-based drug design of Hsp90 inhibitors and evaluation of their biological activities
1004. A New Generation of Hsp90 Inhibitors: Addressing Isoform Selectivity and Heat Shock Induction
1005. USE OF Hsp90 INHIBITORS TO OVERCOME TRASTUZUMAB RESISITANCE IN THE MINOR VARIANT OF HER2 P95HER2 IN BREAST CANCER
1006. Abstract# 4676: A novel class of specific Hsp90 small molecular inhibitors demonstrate in vitro and in vivo anti-tumor activity in the human melanoma cells
1007. A computational study on the role of water and conformational fluctuations in Hsp90 in response to inhibitors
1008. Hsp90 and Its Inhibitors for Cancer Therapy: Use of Nano-delivery System to Improve Its Clinical Application
1009. Identification and synthesis of 3, 4-isoxazolediamides as new class of Hsp90 inhibitors.
1010. Enhanced MHC Class I and II expression induced following staggered combination treatment of human tumor cells with Hsp90 inhibitors and Interferons.(165.16)
1011. 31 Structure-based drug design of Hsp90 inhibitors and their anti-proliferative effects against cancerous diseases
1012. … 90 (Hsp90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors
1013. Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
1014. 35P Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models
1015. Discovery of 2-((4-resorcinolyl)-5-aryl-1, 2, 3-triazol-1-yl) acetates as potent Hsp90 inhibitors with selectivity over TRAP1
1016. Molecular docking studies investigating the interaction of a series of benzoquinone ansamycin Hsp90 inhibitors with NAD (P) H: quinone oxidoreductase 1 (NQO1)
1017. Proteomics Fingerprints of Auy922 and 17-dmag Indicate Common Mechanisms of Action for Hsp90 Inhibitors
1018. Amide-tethered quinoline-resorcinol conjugates as a new class of Hsp90 inhibitors suppressing the growth of prostate cancer cells
1019. Synthesis Of Substituted Pyrrolo [2, 3-D] Pyrimidines As Microtubule-Binding Agents and Hsp90 Inhibitors
1020. The Pursuit of Unshocking Hsp90 Inhibitors: Development of Gedunin and Cruentaren A as Chemical Leads
1021. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma
1022. Hsp90 Inhibitors Prevent NF-κB-Dependent Gene Activation In Human Lung Microvascular Endothelial Cells By Inducing MDM2-Dependent Sirt-2-Promoter Binding
1023. … expression profiling highlights modulation of chromatin-related proteins and chromatin-modifying enzymes in response to Hsp90 inhibitors: Identification of PRMT5 …
1024. Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (Hsp90) inhibitors with significant anti-HIV activity
1025. Improving the Hsp90 Inhibitors Containing 4-(2, 4-Dihydroxyphenyl)-1, 2, 3-thiadiazole Scaffold: Synthesis, Affinity and Effect on Cancer Cells
1026. … vitro study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble Hsp90 inhibitor, 17-AAG …
1027. Hybrids of the Benzofuran Core from Natural Products and the 2, 4‐Dihydroxy‐5‐isopropylbenzene Fragment as Potent Hsp90 Inhibitors: Design, Synthesis and …
1028. High-throughput screens identify Hsp90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer
1029. … : Validation of a multiplex method for detection of several oncosignaling proteins with potential utility for assessment of pharmacodynamic activity of Hsp90 inhibitors
1030. … Ca2+-sensitivity from troponin I phosphorylation by hypertrophic and dilated cardiomyopathy mutations can be reversed by EGCG and related Hsp90 inhibitors
1031. … of truncated tau protein in transgenic rat cortical neurons and human cellular model of tauopathy and Alzheimer’s disease is enhanced by Hsp90 inhibitors
1032. … Discovery and Optimization of 4, 5-Diarylisoxazoles as Potent Dual Inhibitors of Pyruvate Dehydrogenase Kinase (PDHK) and Heat Shock Protein 90 (Hsp90)
1033. Design, synthesis and molecular mechanisms of novel dual inhibitors of heat shock protein 90/phosphoinositide 3-kinase alpha (Hsp90/PI3Kα) against cutaneous …
1034. … abstract Synthesis of 5, 6-dihydro-4H-benzo [d] isoxazol-7-one and 5, 6-dihydro-4H-isoxazolo [5, 4-c] pyridin-7-one derivatives as potential Hsp90 inhibitors
1035. … analogue (HA) histone deacetylase (HDAC) inhibitors (HDIs)-induced apoptosis: New role of HDAC6 inhibition, acetylation and inhibition of Hsp90 and depletion of …
1036. Patent application title: USES OF LABELED Hsp90 INHIBITORS Inventors: Gabriela Chiosis (New York, NY, US) Gabriela Chiosis (New York, NY, US) Tony …
1037. Proteasome Inhibitors Suppress ErbB Family Expression through Hsp90-Mediated Lysosomal Degradation
1038. Targeting Hsp90 chaperone machinery with small molecule inhibitors
1039. Targeting both ends of Hsp90: Chimeric N-terminal inhibitors and novobiocin-derivatized C-terminal inhibitors
1040. The Development of Organelle-localized Hsp90 Isoform-selective Inhibitors
1041. Design of potential Hsp90 and HDAC6 dual inhibitors: virtual screening on Hsp90.
1042. Sensitization of cancer cells to inhibitors of heat shock protein 90 (Hsp90) and proteasome by abamectin
1043. Synthetic and computational efforts toward the understanding and development of novobiocin-derived inhibitors of Hsp90
1044. Design and prediction of new inhibitors of Hsp90 by Virtual Screening
1045. Understanding conformational diversity of heat shock protein 90 (Hsp90) and binding features of inhibitors to Hsp90 via molecular dynamics simulations
1046. Design, Synthesis and Biological Evaluation of Ring-constrained and Biphenyl Derivatives as Hsp90 C-terminal Inhibitors
1047. Unfolding the Hsp90 Foldasome: Structure-Activity Relationship Studies on EGCG and Development of Isoform-Selective Inhibitors
1048. In silico identification and analysis of the binding site for aminocoumarin type inhibitors in the C-terminal domain of Hsp90
1049. Regulation of Calcineurin Signaling Through Blocking of the Chaperone Function of Hsp90 by HDAC Inhibitors
1050. In silico analysis of human Hsp90 for the identification of novel anti-cancer drug target sites and natural compound inhibitors
1051. Impressive Enrichment of Semiempirical Quantum Mechanics‐Based Scoring Function: Hsp90 Protein with 4541 Inhibitors and Decoys
1052. Blocking the protein folding machinery. Rational design of inhibitors of the molecular chaperone Hsp90 as new anticancer agents
1053. Hsp90 Binding Inhibitors Improve Survival and Attenuate the Inflammatory Insult in a Murine Model of Sepsis-Induced Acute Lung Injury.
1054. … OF Hsp90 IMPAIRS DNA-DAMAGE RESPONSE PROTEINS AND INCREASES THE SENSITIVITY OF OVARIAN CARCINOMA CELLS TO PARP INHIBITORS
1055. Direct and Indirect Modulation of EGFR-Mediated Growth Signaling by Hsp90 Inhibition in NSCLCs Resistant to EGFR Tyrosine Kinase Inhibitors in vitro and in vivo
1056. In silico identification of potent inhibitors of heat shock protein 90 (Hsp90) from Indonesian natural product compounds as a novel approach to treat ebola virus …
1057. Retraction notice to”” A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells””.
1058. … Study of the Hsp90 Inhibitor SNX-5422 and Erlotinib in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
1059. Synthesis of Truncated C8-Modified-4′-thionucleosides as Potential Hsp90 Inhibitors
1060. Development of novel Hsp90 inhibitors as potential anticancer agents
1061. HDAC and Hsp90 Inhibitors Down-Regulate PTTG1 / Securin But Do Not Induce Aneuploidy
1062. Stereoselective C, C coupling reactions for the total synthesis of the Hsp90 inhibitor geldanamycin
1063. Preclinical studies on the effectiveness of the new Hsp90 – inhibitor AUY922 alone and in combination with the BCR-ABL inhibitor imatinib for …
1064. Hsp90 inhibitors potentiate PGF2α-induced IL-6 synthesis via p38 MAP kinase in osteoblasts (骨 芽 細胞 に お い てHSP90阻 害 剤 は p38 MAP kinase を 介 し て…
1065. Combined Molecular Modeling Studies of Hsp90 Chaperone Inhibitors by Pharmacophore Model, Molecular Docking and 3D-QSAR
1066. Synergistic therapeutic effect of the combination of the Hsp90 inhibitor AUY922 and the PI3K inhibitor BYL719 with everolimus in neuroendocrine tumors
1067. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
1068. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration
1069. RACK1 competes with Hsp90 for binding to HIF-1α and is required for O2-independent and Hsp90 inhibitor-induced degradation of HIF-1α
1070. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
1071. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells
1072. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis
1073. The Hsp90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms
1074. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
1075. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents
1076. 4-Amino derivatives of the Hsp90 inhibitor CCT018159
1077. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy
1078. (−)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor
1079. A non-toxic Hsp90 inhibitor protects neurons from Aβ-induced toxicity
1080. NVP-AUY922: a small molecule Hsp90 inhibitor with potent antitumor activity in preclinical breast cancer models
1081. Silencing of Hsp90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17 …
1082. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with Hsp90 inhibitor NVP-AUY922
1083. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
1084. The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
1085. A rhizosphere fungus enhances Arabidopsis thermotolerance through production of an Hsp90 inhibitor
1086. Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structure− activity relationships
1087. Gambogic acid, a natural product inhibitor of Hsp90
1088. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas
1089. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin
1090. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with Hsp90 inhibitor and glycolysis inhibitor
1091. Total synthesis of the Hsp90 inhibitor geldanamycin
1092. CUDC-305, a novel synthetic Hsp90 inhibitor with unique pharmacologic properties for cancer therapy
1093. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma
1094. Combination mammalian target of rapamycin inhibitor rapamycin and Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple …
1095. Targeting KRAS-mutant non–small cell lung cancer with the Hsp90 inhibitor ganetespib
1096. First-in-human phase I dose-escalation study of the Hsp90 inhibitor AUY922 in patients with advanced solid tumors
1097. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors
1098. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab
1099. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
1100. 89Zr-trastuzumab PET visualises HER2 downregulation by the Hsp90 inhibitor NVP-AUY922 in a human tumour xenograft
1101. Derrubone, an inhibitor of the Hsp90 protein folding machinery
1102. Phase II study of the Hsp90-inhibitor BIIB021 in gastrointestinal stromal tumors
1103. Efficacy of the Hsp90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
1104. The novel Hsp90 inhibitor STA-9090 exhibits activity against Kit-dependent and-independent malignant mast cell tumors
1105. Functional characterization of the biosynthesis of radicicol, an Hsp90 inhibitor resorcylic acid lactone from Chaetomium chiversii
1106. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
1107. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy
1108. Mechanistic evaluation of the novel Hsp90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma
1109. Concise synthesis of pochonin A, an Hsp90 inhibitor
1110. Hsp90 chaperone inhibitor 17-AAG attenuates Aβ-induced synaptic toxicity and memory impairment
1111. Hsp90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way
1112. Analysis of expression of heat shock protein-90 (Hsp90) and the effects of Hsp90 inhibitor (17-AAG) in multiple myeloma
1113. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17‐AAG)
1114. Identification and initial SAR of silybin: an Hsp90 inhibitor
1115. Molecular characterization of macbecin as an Hsp90 inhibitor
1116. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance
1117. Potentiation of paclitaxel activity by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated …
1118. The Hsp90 inhibitor, 17‐AAG, prevents the ligand‐independent nuclear localization of androgen receptor in refractory prostate cancer cells
1119. … isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90β generates sensitivity to the Hsp90 inhibitor …
1120. The Hsp90 inhibitor NVP-AUY922 potently inhibits non–small cell lung cancer growth
1121. Hsp90 inhibitor 17-AAG selectively eradicates lymphoma stem cells
1122. Ganetespib (STA-9090), a nongeldanamycin Hsp90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non–small cell lung cancer
1123. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer
1124. The novel Hsp90 inhibitor STA‐1474 exhibits biologic activity against osteosarcoma cell lines
1125. Celastrol, a novel Hsp90 inhibitor, depletes Bcr–Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation
1126. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
1127. Hsp90 inhibitor–mediated disruption of chaperone association of atr with Hsp90 sensitizes cancer cells to DNA damage
1128. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1
1129. Hsp90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair
1130. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling
1131. 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation
1132. Chemical proteomics-driven discovery of oleocanthal as an Hsp90 inhibitor
1133. Discovery of a novel Hsp90 inhibitor by fragment linking
1134. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the Hsp90 inhibitor NVP-AUY922 in metastatic breast cancer patients
1135. Antitumor activity of the combination of an Hsp90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
1136. Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs
1137. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the Hsp90 inhibitor geldanamycin.
1138. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model
1139. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
1140. Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells
1141. Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly (ethylene glycol)-b-poly (ε-caprolactone) micelles
1142. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience
1143. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan)+ trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
1144. A novel Hsp90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis
1145. The Hsp90 inhibitor radicicol interacts with the ATP-binding pocket of bacterial sensor kinase PhoQ
1146. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells
1147. Nano self-assembly of recombinant human gelatin conjugated with α-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery
1148. mTOR inhibition potentiates Hsp90 inhibitor activity via cessation of HSP synthesis
1149. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models
1150. The Hsp90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
1151. Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges
1152. Opposite effects of the Hsp90 inhibitor Geldanamycin: induction of apoptosis in PC12, and differentiation in N2A cells
1153. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1
1154. The Hsp90 inhibitor, AT13387, is effective against imatinib-sensitive and-resistant gastrointestinal stromal tumor models
1155. Second-generation Hsp90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells
1156. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo
1157. The Hsp90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and-resistant MET-driven tumor models
1158. Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol
1159. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in …
1160. AUY922, a novel Hsp90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.
1161. Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation
1162. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer
1163. A C-terminal Hsp90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease
1164. SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells
1165. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
1166. Non-invasive MRI tumor imaging and synergistic anticancer effect of Hsp90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model
1167. The Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition
1168. Preclinical activity profile and therapeutic efficacy of the Hsp90 inhibitor ganetespib in triple-negative breast cancer
1169. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies
1170. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer
1171. Phase I/II study of Hsp90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine …
1172. Phase II study of the Hsp90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).
1173. Chemically accessible Hsp90 inhibitor that does not induce a heat shock response
1174. Proteome‐wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells
1175. The Hsp90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage
1176. A novel C-terminal Hsp90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells
1177. Hsp90 inhibitor encapsulated photo-theranostic nanoparticles for synergistic combination cancer therapy
1178. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor
1179. The Hsp90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression
1180. Targeting Hsp90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer
1181. The Hsp90 inhibitor geldanamycin abrogates colocalization of eIF4E and eIF4E-transporter into stress granules and association of eIF4E with eIF4G
1182. Natural product Kongensin A is a non-canonical Hsp90 inhibitor that blocks RIP3-dependent necroptosis
1183. Phase I evaluation of STA-1474, a prodrug of the novel Hsp90 inhibitor ganetespib, in dogs with spontaneous cancer
1184. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
1185. Why is this effective Hsp90 inhibitor not being developed in HER2+ breast cancer?
1186. The anti-myeloma activity of a novel purine scaffold Hsp90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
1187. Antitumor effect of novel Hsp90 inhibitor NVP-AUY922 against oral squamous cell carcinoma
1188. Synergistic action of the novel Hsp90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
1189. The effects of an Hsp90 inhibitor on the paradoxical effect
1190. A phase I study of the Hsp90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas
1191. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the Hsp90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma
1192. Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of Hsp90 inhibitor geldanamycin
1193. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation
1194. First-in-human phase I dose escalation study of a second-generation non-ansamycin Hsp90 inhibitor, AT13387, in patients with advanced solid tumors
1195. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines
1196. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
1197. Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context
1198. Hsp90 inhibitor 17‐AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance
1199. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in …
1200. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts
1201. High-content, high-throughput analysis of cell cycle perturbations induced by the Hsp90 inhibitor XL888
1202. Geldanamycin, a Hsp90 inhibitor, attenuates the hypoxia-induced vascular endothelial growth factor expression in retinal pigment epithelium cells in vitro
1203. The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme
1204. Combination therapy with Hsp90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells
1205. Apoptosis caused by Hsp90 inhibitor geldanamycin in Leishmania donovani during promastigote-to-amastigote transformation stage
1206. Identification of the plant compound geraniin as a novel Hsp90 inhibitor
1207. The Novel Hsp90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations
1208. Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol
1209. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1
1210. Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11
1211. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells
1212. Synthesis and structure–activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor
1213. Stage 1 testing and pharmacodynamic evaluation of the Hsp90 inhibitor alvespimycin (17‐DMAG, KOS‐1022) by the pediatric preclinical testing program
1214. Mode of cell death induced by the Hsp90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX
1215. ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation
1216. The Hsp90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments
1217. Hsp90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells
1218. Phase I trial of the Hsp90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies
1219. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer
1220. The co-chaperone Hch1 regulates Hsp90 function differently than its homologue Aha1 and confers sensitivity to yeast to the Hsp90 inhibitor NVP-AUY922
1221. Targeting GRP75 improves Hsp90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma
1222. Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells
1223. Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS)
1224. Recent updates on the development of ganetespib as a Hsp90 inhibitor
1225. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells
1226. Total synthesis of resorcinol amide Hsp90 inhibitor AT13387
1227. A novel pulse-chase SILAC strategy measures changes in protein decay and synthesis rates induced by perturbation of proteostasis with an Hsp90 inhibitor
1228. Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomas
1229. Hsp90 inhibitor celastrol reinstates growth plate angiogenesis in thiram-induced tibial dyschondroplasia
1230. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90
1231. Novel Hsp90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells
1232. A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
1233. Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an Hsp90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer.
1234. The Hsp90 inhibitor ganetespib radiosensitizes human lung adenocarcinoma cells
1235. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non–small cell lung cancer
1236. Anti‐myeloma activity of the novel 2‐aminothienopyrimidine Hsp90 inhibitor NVP‐BEP800
1237. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer
1238. A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.
1239. Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model
1240. Molecular signature of response and potential pathways related to resistance to the Hsp90 inhibitor, 17AAG, in breast cancer
1241. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down …
1242. Effectively delivering a unique Hsp90 inhibitor using star polymers
1243. Synthesis of Hsp90 inhibitor dimers as potential antitumor agents
1244. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia
1245. Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular …
1246. The Hsp90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
1247. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
1248. A purine scaffold Hsp90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB
1249. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer
1250. Pre-clinical efficacy of PU-H71, a novel Hsp90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma
1251. Presence of MLH1 protein aggravates the potential of the Hsp90 inhibitor radicicol to sensitize tumor cells to cisplatin
1252. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib
1253. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
1254. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the Hsp90 inhibitor ganetespib
1255. The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress
1256. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake
1257. Phase I dose-escalation study of the Hsp90 inhibitor AUY922 in Japanese patients with advanced solid tumors
1258. Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms
1259. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition
1260. Hsp90 inhibitor geldanamycin increases hsp70 mRNA stabilisation but fails to activate HSF1 in cells exposed to hydrostatic pressure
1261. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922
1262. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90
1263. Hsp90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and Hsp90 signaling network complex in leukemia cells
1264. BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway
1265. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemia …
1266. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib
1267. Radicicol, an Hsp90 inhibitor, inhibits intestinal inflammation and leakage in abdominal sepsis
1268. Hsp90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors
1269. Combining an Hsp70 inhibitor with either an N-or C-terminal Hsp90 inhibitor produces mechanistically distinct phenotypes
1270. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation
1271. The novel Hsp90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells
1272. Protection of murine neural progenitor cells by the Hsp90 inhibitor 17‐allylamino‐17‐demethoxygeldanamycin in the low nanomolar concentration range
1273. Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma
1274. The apoptotic effect and associated signalling of Hsp90 inhibitor 17‐DMAG in hepatocellular carcinoma cells
1275. Cellular growth kinetics distinguish a cyclophilin inhibitor from an Hsp90 inhibitor as a selective inhibitor of hepatitis C virus
1276. Hsp90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells
1277. The Hsp90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
1278. Anti‐tumor activity of the Hsp90 inhibitor SNX‐2112 in pediatric cancer cell lines
1279. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71
1280. Hsp90 inhibitor SNX5422/2112 targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell …
1281. IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class
1282. Hsp90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer
1283. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a …
1284. Hsp90 inhibitor antagonizing MIF: the specifics of pleiotropic cancer drug candidates
1285. A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer’s mouse model via an HSF1-mediated …
1286. Elucidation of the Hsp90 C-terminal inhibitor binding site
1287. Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: A plausible therapeutic approach in Alzheimer’s disease
1288. … 1-[4-(2-{6-amino-8-[(6-bromo-1, 3-benzodioxol-5-yl) sulfanyl]-9 H-purin-9-yl} ethyl) piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor
1289. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent …
1290. A Novel Hsp90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer
1291. Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models
1292. 17-AAG, a Hsp90 inhibitor, attenuates the hypoxia-induced expression of SDF-1α and ILK in mouse RPE cells
1293. The Hsp90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal …
1294. A phase I dose escalation study of AUY922, a novel Hsp90 inhibitor, in patients with advanced solid malignancies
1295. Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
1296. An Hsp90 inhibitor, geldanamycin, as a brassinosteroid antagonist: evidence from salt-exposed roots of Vigna radiata
1297. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal‐catalyzed oxidation
1298. … profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the Hsp90 …
1299. Radiosynthesis of the iodine‐124 labeled Hsp90 inhibitor PU‐H71
1300. Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials
1301. Combination therapy of NSCLC using Hsp90 inhibitor and doxorubicin carrying functional nanoceria
1302. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells
1303. Oral administration of an Hsp90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice
1304. Radester, a novel inhibitor of the Hsp90 protein folding machinery
1305. The combination of Hsp90 inhibitor 17 AAG and heavy‐ion irradiation provides effective tumor control in human lung cancer cells
1306. The novel, orally bioavailable Hsp90 inhibitor NVP‐HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan …
1307. Anti-tumor activity of a novel, water soluble Hsp90 inhibitor IPI-504 in multiple myeloma
1308. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib
1309. Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation
1310. Development of synthetic routes to macrocyclic compounds based on the Hsp90 inhibitor radicicol
1311. Inhibition of RPE cell sterile inflammatory responses and endotoxin-induced uveitis by a cell-impermeable Hsp90 inhibitor
1312. Antiproliferative effect of the Hsp90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer
1313. A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report.
1314. Discovery of a novel fluorescent Hsp90 inhibitor and its anti-lung cancer effect
1315. Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents
1316. 17-DMAG, an Hsp90 inhibitor, ameliorates multiple organ dysfunction syndrome via induction of HSP70 in endotoxemic rats
1317. A phase II study of Hsp90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase …
1318. Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network
1319. Elevated expression of Hsp90 and the antitumor effect of an Hsp90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic …
1320. Effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice …
1321. Preclinical pharmacokinetic analysis of SNX-2112, a novel Hsp90 inhibitor, in rats
1322. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells
1323. The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck …
1324. First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (Hsp90) inhibitor AT13387 in refractory solid tumors.
1325. A novel small molecule Hsp90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo
1326. … protozoan infections biochemical characterization of Hsp90 from Plasmodium falciparum and trypanosoma evansi and evaluation of its inhibitor as a candidate drug
1327. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin
1328. Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model
1329. Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells
1330. Transformation of the non-selective aminocyclohexanol-based Hsp90 inhibitor into a Grp94-seletive scaffold
1331. The Hsp90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development
1332. Sti1 is a non-competitive inhibitor of the Hsp90 Atpase binding prevents the N-terminal dimerization reaction during the Atpase cycle
1333. Initial testing (Stage 1) of AT13387, an Hsp90 inhibitor, by the pediatric preclinical testing program
1334. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor
1335. Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation
1336. Preclinical activity of the Hsp90 inhibitor, ganetespib, in ALK-and ROS1-driven cancers.
1337. Process development and scale-up of an Hsp90 inhibitor
1338. … )-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl] methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug …
1339. Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR …
1340. Inhibition of constitutive and cxc-chemokine-induced NF-κB activity potentiates ansamycin-based Hsp90-inhibitor cytotoxicity in castrate-resistant prostate …
1341. Combined Hsp90 and kinase inhibitor therapy: insights from the cancer genome Atlas
1342. Inhibition of thymidine phosphorylase expression by using an Hsp90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells
1343. Dose-escalation study of a second-generation non-ansamycin Hsp90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic …
1344. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art
1345. Divergent synthesis of a pochonin library targeting Hsp90 and in vivo efficacy of an identified inhibitor
1346. The Hsp90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine
1347. Phase IB/II study of the Hsp90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer.
1348. Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development
1349. KU675, a concomitant heat-shock protein inhibitor of Hsp90 and Hsc70 that manifests isoform selectivity for Hsp90α in prostate cancer cells
1350. Low dose Hsp90 inhibitor 17AAG protects neural progenitor cells from ischemia induced death
1351. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients …
1352. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung …
1353. The Hsp90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer
1354. TAS-116, a novel Hsp90 inhibitor, selectively enhances radiosensitivity of human cancer cells to X-rays and carbon ion radiation
1355. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a …
1356. Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 …
1357. First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q
1358. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia …
1359. A novel Hsp90 inhibitor activates compensatory heat shock protein responses and autophagy and alleviates mutant A53T α-synuclein toxicity
1360. A phase I trial of the Hsp90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours
1361. A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel
1362. … -stabilized mesoporous carbon nanospheres as versatile carriers for systemic delivery of amphiphobic SNX-2112 (a Hsp90 inhibitor) with enhanced antitumor effect
1363. Leishmania donovani P23 protects parasites against Hsp90 inhibitor-mediated growth arrest
1364. Effect of Hsp90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation
1365. A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors
1366. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors
1367. Antiproliferative effect of Hsp90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways
1368. Effect of the Hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions
1369. Expression of the protein chaperone, clusterin, in spinal cord cells constitutively and following cellular stress, and upregulation by treatment with Hsp90 inhibitor
1370. Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse …
1371. Preclinical activity of the novel orally bioavailable Hsp90 inhibitor NVP-HSP990 against multiple myeloma cells
1372. 5′‐N‐ethylcarboxamidoadenosine is not a paralog‐specific Hsp90 inhibitor
1373. A novel Hsp90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor …
1374. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK‐independent cell cycle arrest
1375. Phase 1B/2 study of the Hsp90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab …
1376. In silico design of small peptide-based Hsp90 inhibitor: a novel anticancer agent
1377. Determination of SNX-2112, a selective Hsp90 inhibitor, in plasma samples by high-performance liquid chromatography and its application to pharmacokinetics in rats
1378. Efficacy of onalespib, a long-acting second-generation Hsp90 inhibitor, as a single agent and in combination with temozolomide against malignant gliomas
1379. … of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 inhibitor
1380. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
1381. The Hsp90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model
1382. NAD (P) H: Quinone oxidoreductase-1 expression sensitizes malignant melanoma cells to the Hsp90 inhibitor 17-AAG
1383. Experience with Hsp90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma
1384. Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells
1385. Novel Hsp90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma
1386. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells
1387. Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90
1388. Hsp90 inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells
1389. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design
1390. Mitochondrial targeted Hsp90 inhibitor Gamitrinib-TPP (G-TPP) induces PINK1/Parkin-dependent mitophagy
1391. STA-8666, a novel Hsp90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma
1392. BIIB021, a novel Hsp90 inhibitor, sensitizes esophageal squamous cell carcinoma to radiation
1393. Efficient synthesis of Hsp90 inhibitor dimers as potential antitumor agents
1394. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo
1395. Selective KIT inhibitor KI-328 and Hsp90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia
1396. 17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells
1397. The complementation of yeast with human or Plasmodium falciparum Hsp90 confers differential inhibitor sensitivities
1398. Hsp90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio
1399. Convergent synthesis and discovery of a natural product-inspired paralog-selective Hsp90 inhibitor
1400. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program
1401. Dual PI3K-and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: the role of …
1402. Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein
1403. Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the Hsp90 inhibitor …
1404. Preclinical study of AUY922, a novel Hsp90 inhibitor, in the treatment of esophageal adenocarcinoma
1405. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the Hsp90 inhibitor AUY922
1406. Hsp90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2
1407. Small molecule inhibitor screening identifified Hsp90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer
1408. The Hsp90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma
1409. Efficacy of an Hsp90 inhibitor, ganetespib, in preclinical thyroid cancer models
1410. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation
1411. Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti‐inflammatory effects and interacts with glucocorticoid receptor in …
1412. Role of the novel Hsp90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy
1413. Anticancer effects of the Hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells
1414. BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF‑κB pathway …
1415. The decline of porcine sperm motility by geldanamycin, a specific inhibitor of heat-shock protein 90 (Hsp90)
1416. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non …
1417. Assessment of the heat shock protein 90 (Hsp90) inhibitor IPI504 alone or in combination with the tyrosine kinase inhibitor (TKI) imatinib in mice carrying xenografts of …
1418. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90
1419. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG
1420. The Hsp90 inhibitor ganetespib alleviates disease progression and augments intermittent cyclophosphamide therapy in the MRL/lpr mouse model of …
1421. Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery
1422. VEGF downregulation by Hsp90 inhibitor NVP-AUY922 visualized with 89Zr-bevacizumab PET in triple negative breast cancer (TNBC)
1423. In vivo synergism between PARP-inhibitor olaparib and Hsp90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts.
1424. Acquired resistance to Hsp90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells
1425. … anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with …
1426. MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients.
1427. Targeted delivery of chemotherapy using Hsp90 inhibitor drug conjugates is highly active against pancreatic cancer models
1428. The mechanisms of apoptosis in HL-60 cells induced by Hsp90 inhibitor novobiocin
1429. Hsp90 inhibitor SY‑016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian cancer cells
1430. P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats
1431. The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human …
1432. Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α
1433. P-glycoprotein-evading anti-tumor activity of a novel tubulin and Hsp90 dual inhibitor in a non-small-cell lung cancer model
1434. … protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor …
1435. Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells by promoting activation of apoptosis-related proteins
1436. Discovery and pre-clinical profile of SNX-5422: an orally active Hsp90 inhibitor in phase 1 trials for solid and hematological tumors
1437. Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway
1438. Hsp90 inhibitor 17-DMAG exerts anticancer effects against gastric cancer cells principally by altering oxidant-antioxidant balance
1439. Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant …
1440. FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells
1441. Geldanamycin, an inhibitor of Hsp90, potentiates cytochrome P4502E1-mediated toxicity in HepG2 cells
1442. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic …
1443. A phase II study of the Hsp90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
1444. The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes
1445. Dynamic proteomics reveals bimodal protein dynamics of cancer cells in response to Hsp90 inhibitor
1446. Geldanamycin, a potent and specific inhibitor of Hsp90, inhibits gene expression and replication of human cytomegalovirus
1447. A phase I study of Debio 0932, an oral Hsp90 inhibitor, in patients with solid tumors.
1448. Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells
1449. BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models
1450. The Hsp90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells
1451. The Hsp90 inhibitor 17-AAG represses calcium-induced cytokeratin 1 and 10 expression in HaCaT keratinocytes
1452. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy
1453. HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor—PU-H71 (NSC 750424)
1454. Proliferation and apoptosis of leukemia cell line K562 treated with Hsp90 inhibitor 17-DMAG
1455. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line …
1456. Abstract# 4679: The novel Hsp90 inhibitor STA-9090 has potent anticancer activity in in vitro and in vivo models of lung cancer
1457. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma
1458. The novel Hsp90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE
1459. A phase I trial of the heat shock protein 90 (Hsp90) inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, alvespimycin) administered …
1460. The Hsp90 and DNA topoisomerase VI inhibitor radicicol also inhibits human type II DNA topoisomerase
1461. Phase l study assessing a two-consecutive-day (QD× 2) dosing schedule of the Hsp90 inhibitor, AT13387, in patients with advanced solid tumors
1462. Geldanamycin, an inhibitor of Hsp90 increases cytochrome P450 2E1 mediated toxicity in HepG2 cells through sustained activation of the p38MAPK pathway
1463. A phase I trial of the heat shock protein 90 (Hsp90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly …
1464. Alternate Synthesis of Hsp90 Inhibitor AT13387
1465. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
1466. Structural and computational biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-based inhibitor design
1467. A facile and efficient synthesis of d6‐labeled PU‐H71, a purine‐scaffold Hsp90 inhibitor
1468. Discovery of 2′, 4′-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC)
1469. Geldanamycin, an inhibitor of Hsp90, blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains
1470. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases
1471. Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis
1472. Significance of long term pharmacodynamic actions of the Hsp90 inhibitor AT13387
1473. ATP acyl phosphate reactivity reveals native conformations of Hsp90 paralogs and inhibitor target engagement
1474. Activity of the proprietary Hsp90 inhibitor IPI-493 in models of colorectal cancer correlates with RAS pathway activation
1475. IPI-504, a novel orally administered Hsp90 inhibitor, demonstrates anti-tumor effects in EGFR mutant, kinase inhibitor resistant NSCLC
1476. Anti-tumor selectivity of a novel Tubulin and Hsp90 dual-targeting inhibitor in non-small cell lung cancer models
1477. Antiangiogenic activity of the Hsp90 inhibitor ganetespib in pancreatic cancer models
1478. NVP-AUY922, a novel Hsp90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo
1479. Hsp90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells
1480. Effects of Hsp90 inhibitor 17-AAG on cell cycle and apoptosis of human gastric cancer cell lines SGC-7901
1481. In vitro and in vivo antitumor activity of the next generation Hsp90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models.
1482. The Hsp90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells
1483. Radioiodination, biodistribution and PET imaging studies of Hsp90 inhibitor [124I]-PU-H71
1484. Comparative in vitro and in vivo metabolism of MPC-3100, an oral Hsp90 inhibitor, in rat, dog, monkey and human
1485. A combination of histone deacetylase inhibitor LBH589 and the Hsp90 inhibitor 17-AAG is highly active against human CML-BC and AML cells with constitutively …
1486. Preparation of the three C1-C7, C8-C15, and C16-N22 fragments of the Hsp90 inhibitor herbimycin A
1487. A phase I dose-escalation study of the Hsp90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR …
1488. RETRACTED ARTICLE: Potent antitumor activity of Hsp90 inhibitor AUY922 in adrenocortical carcinoma
1489. Hsp90 inhibitor AT-533 blocks HSV-1 nuclear egress and assembly
1490. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening
1491. Combination of the mTOR inhibitor Rapamycin and Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) inhibits proliferation and induces apoptosis …
1492. Hsp90 inhibitor reduces porcine circovirus 2 replication in the porcine monocytic line 3D4/31
1493. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells
1494. Hsp90 inhibitor sensitizes TRAIL-mediated apoptosis via chop-dependent DR5 upregulation in colon cancer cells
1495. Inhibitor binding to Hsp90: a review of thermodynamic, kinetic, enzymatic, and cellular assays
1496. Comparison of long-term pharmacodynamic actions of the synthetic small molecule Hsp90 inhibitor AT13387 in multiple xenograft models
1497. Results of two phase 1 dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422
1498. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)
1499. Image-guided photo-therapeutic nanoporphyrin synergized Hsp90 inhibitor in patient-derived xenograft bladder cancer model
1500. Targeting Hsp90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma
1501. Hsp90 inhibitor STA-9090 potently suppresses secondary KIT kinase-domain mutations responsible for gastrointestinal stromal tumor (GIST) progression …
1502. Pharmaceutical development of IPI‐504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer
1503. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
1504. Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation
1505. BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1
1506. In vitro effect of AZD1208 (Pim Kinase Inhibitor) and 17-AAG (Hsp90 Inhibitor) combination in CLL.
1507. Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced …
1508. … by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor …
1509. Fragment-based drug discovery of the synthetic small molecule Hsp90 inhibitor AT13387
1510. IDH1057, A novel, synthetic, small molecule inhibitor of heat shock protein 90 (Hsp90)
1511. … Protein 90 (Hsp90) Chaperone Function in Patients with Metastatic GIST: Preliminary Results of a Phase I Trial of IPI-504, a Water-Soluble Hsp90 Inhibitor
1512. FS23 binds to the N-terminal domain of human Hsp90: a novel small inhibitor for Hsp90
1513. Ganetespib, an Hsp90 inhibitor, kills Epstein–Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood
1514. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer
1515. Wee1-Hsp90 inhibitor combination treatment: molecular therapy with potentially broad applicability
1516. Hsp90 inhibitor CH5164840 induces micronuclei in TK6 cells via an aneugenic mechanism
1517. Dendritic hexadecapeptide as a cathepsin B degradable carrier for delivery of Hsp90 inhibitor
1518. The Hsp90 inhibitor, AT13387, displays single agent activity in erlotinib-sensitive and-resistant models of EGFR activated NSCLC
1519. Pan-HDAC inhibitor LBH589 depletes EZH2 and DNMT1 by inhibiting chaperone association of Hsp90 with EZH2 and DNMT1.
1520. Clinical efficiency and safety of Hsp90 inhibitor Novobiocin in avian tibial dyschondroplasia
1521. 17AEP-GA, an Hsp90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion
1522. The Hsp90 inhibitor 17-DMAG decreases infection of porcine circovirus type 2 in mice
1523. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction
1524. Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations
1525. Effect of anacardic acid, a Hsp90 inhibitor, on proliferation, invasion and migration of breast cancer MDA-MB-231 cells
1526. Abstract A96: Phase 1 study of Hsp90 inhibitor MPC-3100 in subjects with refractory or recurrent cancer.
1527. Results from phase II trial of Hsp90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
1528. The novel Hsp90 inhibitor NVP-AUY922 shows synergistic anti-leukemic activity with cytarabine in vivo
1529. Synergistic interactions of the Hsp90 inhibitor 17AAG and the PI3K inhibitor LY294002 in non-small cell lung cancer (NSCLC) cell lines involve disruption of Akt and c …
1530. Abstract# 1857: The novel Hsp90 inhibitor, PU-H71, synergizes with cisplatin and blocks invasion and migration of ovarian cell lines.
1531. Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2‐amino‐7‐[4‐fluoro‐2‐(3‐pyridyl) phenyl]‐4‐methyl‐7, 8‐dihydro …
1532. C05. THE NEXT GENERATION Hsp90 INHIBITOR STA-9090, CURRENTLY IN PHASE 2 TRIALS, DISPLAYS POTENT IN VITRO AND IN VIVO ACTIVITY
1533. Phase I study of the Hsp90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.
1534. C-terminal Hsp90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition
1535. Abstract B98: AUY922, a novel Hsp90 inhibitor: Final results of a phase I dose escalation study in Japanese patients with advanced solid malignancies.
1536. Evaluation of the pharmacokinetics and efficacy of a novel pro-drug of the Hsp90 inhibitor, MPC-3100, designed with improved solubility
1537. [2+ 2+ 2] Cyclotrimerization with Propargyl Halides as Copartners: Formal Total Synthesis of the Antitumor Hsp90 Inhibitor AT13387
1538. Consecutive day Hsp90 inhibitor administration improves efficacy in murine models of KIT-driven malignancies and canine mast cell tumors
1539. Study on a Screening Model for Inhibitor of Hsp90 ATPase Activity [J]
1540. Addition of Hsp90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC; results of a randomized Phase 2 study
1541. … study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble Hsp90 inhibitor, 17-AAG, in …
1542. In vitro Cytotoxic Activities of the Oral Platinum (IV) Prodrug Oxoplatin and Hsp90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
1543. Proteasome inhibitor-induced cleavage of Hsp90 is mediated by ROS generation and caspase 10-activation in human leukemic cells
1544. Hsp90 Inhibitor Can Inhibit UV Carcinogenesis
1545. A novel, orally active, small molecule Hsp90 inhibitor.
1546. … of two novel Hsp90 proteins in Babesia orientalis: molecular characterization, and computational analyses of their structure, function, antigenicity and inhibitor …
1547. The Hsp90 inhibitor, 17-Allylamino-17-Demethoxygeldanamycin (17AAG) abrogates the G2/M DNA damage checkpoint and induces apoptosis selectively in p53 …
1548. Design of novel Geldanamycin analogue Hsp90 alpha-inhibitor in silico for breast cancer therapy
1549. CNF2024-The first clinical stage synthetic oral Hsp90 inhibitor
1550. … into whether the rapamycin inhibition of heat shock transcription factor (Hsf1) can prevent the Hsf1 activation that results from treatment with an Hsp90 inhibitor
1551. Discovery of the Serenex Hsp90 Inhibitor, SNX5422
1552. The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox
1553. The Hsp90 inhibitor, radicicol, attenuates bacterial lipopolysaccharide-induced endothelial permeability.
1554. Immunotherapeutic targeting of Hsp90 client proteins in BRAF-inhibitor resistant melanoma
1555. Discovery of licochalcone a as a natural product inhibitor of Hsp90 and its effect on gefitinib resistance in non-small cell lung cancer (NSCLC)
1556. Radicicol, a Hsp90 inhibitor, inhibits intestinal inflammation and leakage in abdominal sepsis
1557. Inhibitor-κB kinase attenuates Hsp90-dependent endothelial nitric oxide synthase function in vascular endothelial cells
1558. Effect of Hsp90 inhibitor novobiocin on STI571 resistant K562/G01 cells
1559. Antiviral evaluation of an Hsp90 inhibitor, gedunin, against dengue virus
1560. Metabolism and excretion of 6-chloro-9-(4-methoxy-3, 5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an Hsp90 inhibitor, in rats and dogs and assessment of its …
1561. Inhibition of thyroid cancer proliferation in vitro by a novel small molecule Hsp90 inhibitor.
1562. Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor
1563. Favorable interactions between fenretinide and the Hsp90 inhibitor 17AAG in neuroblastoma
1564. Hsp90 inhibitor is a good candidate for effective combination therapy with carbon ions
1565. Polymer mediated transport of the Hsp90 inhibitor LB76, a polar cyclic peptide, produces an Hsp90 cellular phenotype
1566. A purine scaffold Hsp90 inhibitor has antitumor activity in KSHV-associated malignancies by suppressing vFLIP
1567. 17-DMAG, an Hsp90 inhibitor, ameliorates ovariectomy-induced obesity in rats
1568. Expression of Hsp90 in a panel of human tumor explants and its relation to response to treatment with the Hsp90 inhibitor 17-AAG.
1569. Hsp90 Inhibitor Geldanamycin as a Radiation Response Modificator in Human Blood Cells
1570. Preclinical safety profile of tanespimycin (KOS-953)-a heat shock protein 90 (Hsp90) inhibitor
1571. Discovery of an L-alanine ester prodrug of the Hsp90 inhibitor, MPC-3100
1572. BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies
1573. Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG
1574. Potent anticancer actions of the Hsp90 inhibitor STA-9090 in wild-type EGFR models of lung cancer
1575. The Hsp90 inhibitor, onalespib (AT13387), delays the emergence of resistance to erlotinib in an EGFR-driven xenograft model
1576. NVP-AUY922, a novel diarylisoxazole resorcinol Hsp90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts
1577. Hsp90 inhibitor STA-9090 induces HIF-1α degradation in the hypoxic regions of solid tumors
1578. … POSTER Modulation of the Hsp90 co-chaperone AHA1 affects client protein activity and increases cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17 …
1579. Combination of the Hsp90 inhibitor, 17AAG, with taxol in human ovarian tumour cell lines
1580. Effects of cotreatment or sequence treatment with Hsp90 C-terminal inhibitor NB and Hsp90 N-terminal inhibitor GA on leukemia cells
1581. Hsp90 inhibitor induces KG-1a cell differentiation and apoptosis via Akt/NF-κB signaling
1582. Delivery of Hsp90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload
1583. Acquired resistance to Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in adult and pediatric glioblastoma cell lines
1584. Simultaneously targeting hypoxic cancer cells by Hsp90 inhibitor and glycolysis inhibitor in pancreatic cancer therapy
1585. ATPS-05CHARACTERIZATION OF THE ACTIVITY OF AT13387, A NOVEL SECOND GENERATION Hsp90 INHIBITOR AGAINST GLIOMAS
1586. Blood-brain-barrier–permeable Hsp90 inhibitor reduces soluble tau burden in a mouse model of Alzheimer’s disease
1587. Abstract B199: In vitro and in vivo efficacy of the novel Hsp90 inhibitor STA‐9090 and its synergy with paclitaxel
1588. The effect of EC78, a novel Hsp90 inhibitor alone and in combination with radiation in head and neck squamous cell carcinoma
1589. Progesterone Receptor Chaperone Complex–Based High-Throughput Screening Assay: Identification of Capsaicin as an Inhibitor of the Hsp90 Machine
1590. Hsp90 inhibitor NMS-E973 exerts the anticancer effect against glioblastoma via induction of PUMA-mediated apoptosis
1591. Model system identifies kinetic driver of Hsp90 inhibitor activity against African trypanosomes and Plasmodium falciparum
1592. IPI-504, a novel Hsp90 inhibitor is effective in EGFR T790M and non-T790M gefitinib-resistant lung cancer cell lines.
1593. Ribosome Profiling Reveals Hsp90 Inhibitor Effects on Stage-Specific Protein Synthesis in Leishmania donovani
1594. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922
1595. Phase I study of vemurafenib and heat shock protein 90 (Hsp90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.
1596. Hsp90 inhibitor induces cell cycle arrest and apoptosis of early embryos and primary cells in pigs
1597. Hsp90 inhibitor geldanamycin reverts IL-13–and IL-17–induced airway goblet cell metaplasia
1598. Hsp90 inhibitor STA-9090 enhances the activity of standard of care therapies in erlotinib-sensitive and-resistant NSCLC models
1599. Abrogation of hsp70 induction: A strategy to enhance the antileukemia effects of Hsp90 inhibitor 17-allylamino-demethoxy geldanamycin (17-AAG)
1600. Hsp90 Inhibitor 17-AAG Inhibits Multiple Myeloma Cell Proliferation by Down-regulating Wnt/β-Catenin Signaling Pathway
1601. Hsp90 inhibitor 17-DMAG effectively alleviated the progress of thoracic aortic dissection by suppressing smooth muscle cell phenotypic switch
1602. TM-03THE Hsp90 INHIBITOR GANETESPIB IS AN EFFECTIVE THERAPY FOR GLIOBLASTOMA THAT BLOCKS EGFR-DRIVEN TUMOR GROWTH
1603. Inhibition of Hsp90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells
1604. Preclinical testing demonstrates strong activity of STA-12-8666, an Hsp90 inhibitor-SN-38 conjugate, in small cell lung cancer (SCLC)
1605. OA 12.02 final results of a phase 2 study of the Hsp90 Inhibitor Luminespib (AUY922) in NSCLC patients harboring EGFR Exon 20 insertions
1606. A phase I study of the Hsp90 inhibitor AUY922 plus capecitabine for the treatment of patients with advanced solid tumors
1607. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer
1608. Biological effects of the novel small molecule Hsp90 inhibitor SNX-2112 as a single agent and in combination with Erlotinib in non-small cell lung cancer models
1609. P2. 13-39 a phase Ib trial of the Hsp90 inhibitor AUY922 in combination with Pemetrexed in metastatic non-squamous, non-small cell lung cancer patients
1610. Mechanism of Inhibition of Hsp90 Dimerization by Gyrase B Inhibitor Coumermycin A1 (C–A1) Revealed by Molecular Dynamics Simulations and Thermodynamic …
1611. A novel, selective, orally active, potent small molecule inhibitor of Hsp90
1612. 2‐phenylethynesulphonamide (PFT‐μ) enhances the anticancer effect of the novel Hsp90 inhibitor NVP‐AUY922 in melanoma, by reducing GSH levels
1613. The novel Hsp90 inhibitor IPI-504 synergizes with bortezomib in mantle cell lymphoma cells by targeting both NF-kappaB signaling and unfolded protein response …
1614. Abstract A110: A phase 1 study of PF‐04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with …
1615. A novel Hsp90 inhibitor, 17-DMAG, induces Tax down-regulation and its oral administration to ATL-model mice intervenes against the infiltration property of the ATL …
1616. 17-AAG (KOS-953), an inhibitor of Hsp90 function, significantly enhances the cytotoxicity of anticancer drugs: An effective approach for combination therapy
1617. Part I of GANNET53: A European multicenter Phase I/II trial of the Hsp90 inhibitor Ganetespib combined with weekly Paclitaxel in women with high-grade, platinum …
1618. Triptolide, a Hsp90 middle domain inhibitor, induces apoptosis in triple manner
1619. Molecular dynamics simulations of Hsp90 with an eye to inhibitor design
1620. 1479PDPhase II study of TAS-116, an oral inhibitor of heat shock protein 90 (Hsp90), in metastatic or unresectable gastrointestinal stromal tumor refractory to …
1621. … (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin,(17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (Hsp90), in patients with …
1622. Chetomin as a Potent Hsp90 Inhibitor
1623. Thermodynamics of Natural and Synthetic Inhibitor Binding to Human Hsp90
1624. Development of Polymeric-Drug Conjugates for Delivering the Hsp90 Inhibitor SNX5422
1625. Hsp90 Inhibitor Treatment for Cushing Syndrome and Other Diseases
1626. Analysis of Genes Regulated by Hsp90 Inhibitor Geldanamycin in Neurons
1627. Repositioning Irsogladine to Hsp90 Inhibitor
1628. A novel inhibitor to disrupt Hsp90-Cdc37 interaction against pancreatic cancer
1629. Identification of Hsp90 inhibitor sensitizers through pooled RNA interference screen
1630. Abstract B19: The Hsp90 inhibitor, AT13387, is effective against multiple mechanisms of kinase inhibitor resistance
1631. Abstract B90: Hsp90 inhibitor NVP-AUY922 sensitizes intrinsic MEK inhibitor Trametinib-resistant NSCLC cells harboring KRAS mutation
1632. Preclinical efficacy of PF-04942847, a novel Hsp90 inhibitor, in osteosarcoma
1633. Hsp90 Inhibitor Enhances the Pgd2-stimulated Hsp27 Induction in Osteoblasts
1634. Novel Hsp90 inhibitor, STA-9090, for combination with radiotherapy
1635. A new Hsp90 inhibitor as therapeutic agent for bladder cancer.
1636. Hypoxic Radiosensitization By DMAG, an Hsp90 Inhibitor
1637. A novel small molecule inhibitor of heat shock protein 90 (Hsp90)
1638. Preclinical evaluation of WXFL1024H251, a potent second-generation Hsp90 inhibitor
1639. Synthesis of the seco‐Limonoid BCD Ring System Identifies a Hsp90 Chaperon Machinery (p23) Inhibitor
1640. Combinatorial targeting of oncogenesis via a novel rationally designed Hsp90 inhibitor
1641. Development of the high-throughput screening fluorescence polarization assay for Hsp90 inhibitor
1642. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer
1643. The Hsp90 inhibitor Ganetespib: A Potential Effective
1644. Hsp90 inhibitor, 17-DMAG, enhances radiosensitivity of human cancer cells
1645. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain
1646. Abstract B1: Targeting KRAS mutant NSCLC with the Hsp90 inhibitor ganetespib
1647. FS-108, an Hsp90 inhibitor, impairs survival and motility of oncogene addicted cancer cells
1648. Hsp90 Inhibitor Strengthens Atp-stimulated Interleukin-6 Synthesis in Osteoblasts
1649. Hsp90 inhibitor drug conjugates (HDCs): Proof of concept in preclinical studies
1650. The design and synthesis of a novel orally available Hsp90 inhibitor CH5164840
1651. Phase 1 study of onalespib, Hsp90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors.
1652. … Inhibitor Enhances Hsp90 Inhibitor-mediated Abrogation of Hsp90 Chaperone Function and Potentiates the Cytotoxicity of Hsp90 Inhibitor in Chemo-resistant …
1653. Hsp90 inhibitor has a possibility to overcome imatinib resistance in gastrointestinal stromal tumors
1654. Effectiveness of the combined treatment with Hsp90 inhibitor and heavy ion irradiation
1655. The novel Hsp90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma
1656. Abstract A212: A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor‐induced apoptosis in HCT116 colon carcinoma cells
1657. Hsp90 and histone deactylase inhibitor have synergistic activity against synovial sarcoma.
1658. Hsp90 inhibitor (NVP-AUY922) enhances anti-cancer effect of Bcl-2 inhibitor (ABT-737) in small cell lung cancer
1659. Abstract# 4690: Preclinical characterization of the Hsp90 inhibitor XL888 in melanoma models
1660. Moleculary Targeted Nanomedicine: Role of Hsp90 Inhibitor and Sophorolipids
1661. Discovery of a novel small inhibitor RJ19 targeting to human Hsp90
1662. Molecular profile and anti-myeloma activity of the novel Hsp90 inhibitor NVP-AUY922
1663. Inhibition of signal transduction by the Hsp90 inhibitor sensitizes human tumor cells to radiation
1664. Chemical approaches to development of mitochondrial-targeted Hsp90 inhibitor in anti-cancer therapeutics: Mechanism and structure change of mitochondrial Hsp90
1665. Essential oil from Cymbopogon flexuosus as the potential inhibitor for HSP90
1666. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation
1667. Preclinical antitumor activity of SST0116CL1, a novel heat shock protein 90 (Hsp90) inhibitor
1668. Radiosensitization induced by 17DMAG: An orally bioavailable inhibitor of HSP90
1669. AT13387, an Hsp90 inhibitor, is effective in both vemurafenib-sensitive and-resistant melanoma models
1670. Treatment of Arabidopsis thaliana seeds with an Hsp90 inhibitor increases plant resistance
1671. Treatment of advanced bronchoalveolar carcinoma with the Hsp90 inhibitor STA-9090.
1672. Abstract B100: Preclinical evaluation of a novel Hsp90 inhibitor HSP990 in glioblastoma multiforme.
1673. The investigation of AT7519 (CDK inhibitor) and AT13387 (Hsp90 inhibitor) as novel therapies for the treatment of pancreatic ductal adenocarcinoma
1674. Identification of vibsanin A analog as a novel Hsp90 inhibitor
1675. Abstract# 4678: Preclinical anti-myeloma activity of the novel Hsp90 ATPase inhibitor NVP-BEP800
1676. Overcoming acquired resistance to BRAF inhibitors in melanoma with the Hsp90 inhibitor ganetespib
1677. Identification of the ellagitannin geraniin as a novel Hsp90 inhibitor
1678. Effect of Hsp90 inhibitor ganetespib on stemness in small cell lung cancer
1679. Chemotherapeutic potential of Hsp90 and biological evaluation of a novel Hsp90 inhibitor
1680. Gene Expression Profile of Apoptosis in Leukemia Cells Induced by Hsp90 Selective inhibitor 17-AAG
1681. NVP-AUY922: A novel small molecule Hsp90 inhibitor with potent in vivo antitumor efficacy
1682. Hsp90 inhibitor AUY922 abrogates mTOR inhibitor AZD8055-induced up-regulation of HER2/HER3 and potentiates antiproliferative activity in human breast cancer …
1683. The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor
1684. The Hsp90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and crizotinib-resistant MET-driven renal tumor models
1685. The Hsp90 inhibitor ganetespib is a potent chemosensitizer in preclinical colorectal cancer models
1686. Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity
1687. Results of toxicology studies with MPC-3100, an oral Hsp90 inhibitor.
1688. Identification and validation of serum biomarkers for clinical assessment of Hsp90 inhibitor therapy
1689. AT-533, a Hsp90 inhibitor, attenuates HSV-1-induced inflammation
1690. Hsp90 Inhibitor, 17-AAG, Affects Meiotic Maturation and Preimplantation Embryos Development in Pigs.
1691. Novel in vivo pan-Hsp90 family protein inhibitor, Panvotinib-401, showed potent anticancer activities without HSF1 activation
1692. The novel Hsp90 inhibitor STA-12-1474 exhibits biologic activity against canine osteosarcoma cell lines
1693. Abstract B88: Mechanisms of resistance to the Hsp90 inhibitor ganetespib in triple negative breast cancer
1694. Proteasome inhibitor‐induced protein aggregation is regulated via HSP90, HDACs and microtubulus stability in ARPE‐19 cells
1695. Hsp90-inhibitor drug conjugates (HDC): Novel tumor-selective drug delivery platform with unprecedented anticancer activity
1696. NVP-AUY922/VER-52296: A novel 3, 4 diarylisoxazole Hsp90 chaperone inhibitor discovered via structure-based drug design
1697. Hsp90-inhibitor Ganetesbip potentiates radiosensitizing and chemosensitizing effects of hyperthermia
1698. Development of a noninvasive assay to determine drug concentration in tumor during Hsp90 inhibitor therapy
1699. (-)-Epigallocatechin-3-gallate, Found in the Green Tea Extract, is a Novel Hsp90 Inhibitor
1700. Molecular detection of Hsp90 inhibitor suppressing PCV2 replication in host cells
1701. Antitumor activity of MPC-3100, a synthetic, orally bioavailable Hsp90 inhibitor, in animal models
1702. The effects of Hsp90 inhibitor DMAG on the leukemia cell line HL-60
1703. The Hsp90 inhibitor 17-AAG improves chemoresistance of cisplatin-resistant esophageal squamous cell carcinoma cell lines
1704. Synthesis of isotope‐labeled Hsp90 inhibitor: [13CD3] and [14C]‐TAK‐459
1705. Hsp90 inhibitor, 17-allylaminogeldanamycin, inhibits cell growth of lung cancer cell lines associated with overexpression of Hsp90 on lung cancer tissues.
1706. The Hsp90 inhibitor ganetespib potentiates effect of ionizing radiation in human non-small cell lung cancer
1707. DEBIO0932, an Hsp90 inhibitor downregulates key signaling pathways and sensitizes glioma cells to temozolomide
1708. The Research and Analysis of Global Market about Hsp90 Inhibitor from Microbiology
1709. Hsp90 inhibitor 17-DMAG enhances EphA2+ tumor cell recognition by specific CD8+ T cells (40.27)
1710. Novel inhibitor of Hsp90-PU-H71 exhibits significant activity in Ewing sarcoma pre-clinical models.
1711. Synthesis of an 18F labeled pyrazole-based Hsp90 inhibitor for PET imaging of cancers
1712. 601 The Antimyeloma Activity of PU-H71, a Novel Purine Scaffold Hsp90 Inhibitor, is via Inhibition of Both HSP90A and HSP90B1
1713. The Hsp90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC
1714. Efficacy of the Hsp90 inhibitor NVP-AUY922 correlates with decreased vessel permeability and reduced interstitial fluid pressure
1715. Abstract# LB-86: Probing cancer-specific activating signaling pathways through a tumor-specific Hsp90 inhibitor
1716. Ganetespib, an Hsp90 Inhibitor, Sensitizes Colorectal Cancers to the Effects of Ionizing Radiation
1717. MPC-3100, a synthetic Hsp90 inhibitor, induces biomarker changes in vitro and in vivo
1718. ET-14. PRECLINICAL EVALUATION OF NXD30001, A NOVEL Hsp90 INHIBITOR, FOR EFFICACY IN GLIOMA
1719. Identification and development of NVP-HSP990, a potent and orally active Hsp90 inhibitor for cancer treatment
1720. Potent antitumor activity of the Hsp90 inhibitor SNX-2112 in type 1 papillary renal cell carcinoma
1721. The Hsp90 Inhibitor 17-AAG Prevents Aberrant Endocytosis Mediated By The Rhodopsin Retinitis Pigmentosa R135L Mutation
1722. Abstract LB-140: The Hsp90 inhibitor ganetespib overcomes EGFR-based intratumoral heterogeneity to block glioma proliferation
1723. Determining the Effect of Hsp90 Inhibitor Geldanamycin on Herpes Simplex Virus Type-1 Production in Infected Vero Cells
1724. Effect of the Hsp90 Inhibitor KW-2478 on HepG2 Cells.
1725. Abstract LB-187: Hsp90 inhibitor SNX-2112 enhances neoantigen presentation on the surface of tumor cells
1726. Signaling Profile and Anti-Tumor Activity of the Novel Hsp90 Inhibitor NVP-AUY922 in Multiple Myeloma.
1727. The Hsp90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells
1728. Preclinical evaluation of the novel, potent diarylisoxazole resorcinol Hsp90 inhibitor NVP-AUY922 in adult and pediatric glioblastomas
1729. Activity of PU-H71, a novel Hsp90 inhibitor, and bortezomib in Ewing sarcoma preclinical models.
1730. The Hsp90 Inhibitor, AUY-922 Reduces Pulmonary Fibrosis and Airway Dysfunction in Mice Exposed to HCl
1731. Abstract# 5632: NVP-BEP800: an orally bioavailable small molecule Hsp90 inhibitor with potent in vivo antitumor activity
1732. 52. A Novel Small Molecule Hsp90 Inhibitor With Antiproliferative Effects in Differentiated and Anaplastic Thyroid Cancers
1733. Targeting Hsp90 using EC154, a novel synthetic Hsp90 inhibitor, impairs multiple signaling pathways in human gastric and pancreatic cancer cells and reduces tumor …
1734. Preclinical evaluation of the Hsp90 inhibitor KW-2478 in combination with bortezomib as a treatment for multiple myeloma
1735. Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold Hsp90 inhibitor.
1736. Clinical and biological significances of heat shock protein 90 (Hsp90) in human nasopharyngeal carcinoma cells and anti-cancer effects of Hsp90 inhibitor
1737. Antitumor activity of MPC-3100, a synthetic Hsp90 inhibitor, in combination with erlotinib and sorafenib
1738. Biological Evaluation of Natural Product as a Potent Hsp90 Inhibitor.
1739. Design, synthesis, and biological evaluation of small molecule as Hsp90 inhibitor
1740. 26 BC265: A Nonquinone Ansamycin Hsp90 Inhibitor Developed Using Biosynthetic Medicinal Chemistry
1741. Experimental study on mouse bone marrow micronucleus of a novel Hsp90 inhibitor-SNX-2112
1742. Abstract B101: Safety, tolerability, and pharmacokinetics of IPI-493, an oral Hsp90 inhibitor, in patients with advanced cancers.
1743. Abstract A213: Potent anticancer activity in vitro and in vivo by NMS‐E973, a novel synthetic inhibitor of HSP90
1744. The Hsp90 inhibitor PU-H71 is a potent suppressor of metastasis in triple-negative breast cancer models
1745. Abstract A218: Pharmacokinetic (PK) and pharmacodynamic (PD) data for MPC‐3100, a fully synthetic Hsp90 inhibitor, in cancer patients
1746. BJ-B11, an Hsp90 Inhibitor, Constrains the Proliferation and Invasion of Breast Cancer Cells
1747. Antitumor activity of heat shock protein 90 (Hsp90) inhibitor AT13387 in head and neck squamous cell carcinoma
1748. Preclinical efficacy of the Hsp90 inhibitor SNX-5422 in targeting C481S mutant BTK and ibrutinib resistant CLL
1749. Hsp90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
1750. The Hsp90 Inhibitor Radicicol As A Bioinformatically-Derived Drug For M2 Macrophage Phenotype Inhibition
1751. Multimodal action of the Hsp90 inhibitor STA-9090 in treating cancer cells with activated JAK/STAT signaling
1752. A specific Hsp90 small molecular inhibitor demonstrates anti-tumor activity in melanoma cells through V600E B-Raf protein degradation
1753. Abstract# 1853: Cancer cells harboring MET gene amplification are sensitive to Hsp90 inhibitor 17-AAG
1754. STA-12-8666: a first-in-class Hsp90 inhibitor drug conjugate (HDC) designed to selectively deliver chemotherapy to tumors
1755. A Novel Hsp90 Inhibitor to Disrupt HSP90/p50CDC37 Complex for Pancreatic Cancer Therapy.
1756. Activity of the heat shock protein 90 (Hsp90) inhibitor, SNX-2112, in pediatric cancer cell lines.
1757. Abstract# 4682: BIIB021, a fully synthetic oral small molecule inhibitor of Hsp90, shows anti-tumor activity in multiple xenograft models.
1758. Activity of Hsp90-inhibitor drug conjugate (HDC) STA-12-8666 in preclinical models of pediatric sarcoma.
1759. The advances of the Hsp90 inhibitor NVP-AUY922: applied alone or in combination with anti-tumor treatment
1760. The Hsp90 inhibitor, 17-AAG, reduces pulmonary arterial calcineurin activity in monocrotaline-induced pulmonary arterial hypertension (PAH)
1761. Targeting Hsp90 using EC154, a novel synthetic Hsp90 inhibitor, impairs multiple oncogenic signaling pathways in human gastric and pancreatic cancer cells and …
1762. Pre-clinical and clinical evaluation of the heat shock protein 90 (Hsp90) inhibitor 17-allylamino, 17-demethoxygeldanamycin.
1763. Human cytochrome P450 and UDP-glucuronosyltransferase reaction phenotyping of MPC-3100, an oral Hsp90 inhibitor.
1764. Hsp90 Inhibitor-Based Strategies for Cancer Therapy: Advancing Toward Clinical Impact
1765. Protein–protein inhibitor designed de novo to target the MEEVD region on the C-terminus of Hsp90 and block co-chaperone activity
1766. Activity of IPI-504, a water-soluble Hsp90 inhibitor, combined with bortezomib in a human multiple myeloma xenograft model
1767. Abstract B105: Ganetespib, a unique resorcinolic Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile in preclinical models.
1768. Hsp90 inhibitor SY-016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian
1769. Topically applied Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin inhibits ultraviolet radiation-induced development of cutaneous squamous cell …
1770. Hsp90 inhibitor induces nuclear translocation of HSF1 predominantly in hippocampal CA1 region
1771. Post-treatment with the heat shock protein 90 (Hsp90) inhibitor, AUY-922, reduces lung Hsp90 tyrosine (Y) phosphorylation and pulmonary inflammation in LPS …
1772. The Hsp90 Inhibitor, 17-AAG Prevents The Progression Of Monocrotaline-Induced Right Ventricular Hypertrophy And Pulmonary Arterial Hypertension
1773. Abstract B105: Hsp90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes
1774. Combined treatment wth Hsp90 inhibitor and TRAIL down-regulated NFκB activity through their effects on the death receptor complex.
1775. Proteomic analysis of Hsp90 inhibitor effects on human leukemia cells
1776. Abstract# 1922: Antitumor activity of CUDC-305, a novel oral Hsp90 inhibitor, in solid and hematological tumor xenograft models
1777. Synthesis and biological evaluation of geldanamycin–ferulic acid conjugate as a potent Hsp90 inhibitor
1778. Hsp90 inhibitor NVP-AUY922 exhibits the potent antiproliferative effect in gastrointestinal cancer cells with a lack of PTEN expression
1779. Hsp90 inhibitor DPB induces autophagy and more effectively apoptosis in A549 cells combined with autophagy inhibitors
1780. A Hsp90 inhibitor, AUY922, is effective to overcome the MET-and AXL-mediated resistance to EGFR-TKI in lung cancer
1781. Abstract# 5649: Pharmakokinetic/phamacodynamic relationship of the Hsp90 inhibitor NVP-AUY922 in human xenografts and patients in a clinical Phase I trial
1782. MEK-inhibitor PD184352 enhances the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922: the role of cell type and drug-irradiation schedule
1783. Discovery of a novel butein derivative as a promising Hsp90 inhibitor
1784. Cassette dosing in tumor bearing animals for the discovery of NVP-AUY922, a novel Hsp90 inhibitor.
1785. Antiproliferative effects and signaling profiles of the novel Hsp90 inhibitor NVP-AUY922 in non-small cell lung cancer
1786. Pharmacokinetics (PK) and toxicology of KOS-1022, an orally administered heat shock protein 90 (Hsp90) Inhibitor
1787. The novel Hsp90 inhibitor, PF-04929113, inhibits AR activity and osteoclastogenesis and delays castrate-resistant LNCaP prostate cancer tumor growth
1788. Effect of Hsp90 inhibitor NVP-AUY922 with radiation on lung adenocarcinoma cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors
1789. Evaluating the Hsp90 Inhibitor Ganetespib as a Radiosensitizing Agent in Breast Cancer Models In Vitro
1790. Modulation of AHA1: A novel therapeutic strategy to increase cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG)
1791. Abstract B14: Hsp90-inhibitor drug conjugate STA-12-8666 demonstrates complete tumor regression in preclinical models of pediatric sarcoma
1792. Development and validation of a highly sensitive ELISA method for the quantitation of Hsp70-a tumor biomarker associated with Hsp90 inhibitor therapy
1793. Abstract# 3998: 89Zr-trastuzumab immunoPET visualizes HER2 downregulation induced by the Hsp90 inhibitor NVP-AUY922 in human tumor xenograft
1794. Role of NAD (P) H: quinone oxidoreductase 1 (NQO1) in the cytotoxicity of the Hsp90 inhibitor 17AAG in human pancreatic cancer cells
1795. Abstract B184: Hsp90 inhibitor STA‐9090 potently suppresses heterogeneous KIT kinase‐domain mutations responsible for gastrointestinal stromal tumor …
1796. Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment
1797. A research of apoptosis-inducing effects of APL cells NB4 by an Hsp90 inhibitor HDN-1
1798. Retraction: Novel Hsp90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig 2-Positive Glioma Tumor–Initiating Cells
1799. Abstract A217: The Hsp90 inhibitor AT13387 demonstrates potent antitumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor …
1800. Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation
1801. Zr-bevacizumab PET imaging of early anti-angiogenic tumor response to treatment with Hsp90 inhibitor NVP-AUY922
1802. Non-steroidal anti-inflammatory drugs sensitize CD44-overexpressing cancer cells to Hsp90 inhibitor through autophagy activation
1803. Abstract C130: The Hsp90 inhibitor ganetespib promotes the degradation of FGFR3 in bladder cancer models and induces regression in tumors harboring oncogenic …
1804. Hs-27, a Novel Hsp90 Inhibitor, Exhibits Diagnostic and Therapeutic Potential in Triple Negative Breast Cancer
1805. Abstract A214: A novobiocin analogue Hsp90 inhibitor induces apoptosis and has potent antitumor effects in head and neck squamous cell cancer in vivo
1806. The Hsp90 inhibitor FW-04-806 suppresses Bcr/Abl-mediated growth of leukemia cells by inhibiting proliferation and inducing apoptosis
1807. PO-440 Targeting of triple negative breast tumours using liposomes as drug delivery systems for sirna and Hsp90 inhibitor
1808. Abstract A215: Hsp90 inhibitor IPI‐504 demonstrates antitumor activity against a panel of neuroendocrine/carcinoid cell lines in vitro and in vivo
1809. Hsp90 inhibitor 17‐AAG prevents apoptosis of cardiomyocytes via miR‐93–dependent mitigation of endoplasmic reticulum stress
1810. Clinical Development of Gamitrinib, a Novel Mitochondrial-Targeted Small Molecule Hsp90 Inhibitor
1811. … protozoan infections: biochemical characterization of Hsp90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug
1812. Differing mechanisms of synergistic interaction of the Hsp90 inhibitor 17-AAG and TRAIL in resistant colon cancer cell lines
1813. Preclinical evidence of synergism between DNA damaging agents and the Hsp90 Inhibitor, 17-DMAG, in tumors with mutant p53
1814. Abstract# LB-7: Targeting triple-negative breast cancer via PU-H71, a purine-scaffold heat shock protein 90 (Hsp90) inhibitor
1815. C76 HEAT SHOCK PROTEIN: The Hsp90 Inhibitor Radicicol As A Bioinformatically-Derived Drug For M2 Macrophage Phenotype Inhibition
1816. Hsp90 inhibitor 17-allylamino-geldanamycin enhances sensitivity to double-strand DNA break-inducing agents (platinum and PARP inhibitors) in epithelial ovarian …
1817. Combining the Hsp90 inhibitor, AT13387, with vemurafenib delays the emergence of resistance in a preclinical model of BRAF V600E mutant melanoma.
1818. Mechanism of resistance to 17-DMAG, an Hsp90 inhibitor, in lung cancer cell lines with ALK rearrangement
1819. Identification of synergistic drug combinations with the oral Hsp90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancer
1820. Radiosensitization by post-irradiation treatment with an Hsp90 inhibitor, 17-DMAG, in the p53 mutant pancreatic cancer cell line, MiaPaca2
1821. Expedient Access to 2‐Benzazepines by Palladium‐Catalyzed C− H Activation: Identification of a Unique Hsp90 Inhibitor Scaffold
1822. Potent activity of the heat shock protein 90 (Hsp90) inhibitor, 17AAG in head and neck squamous cell carcinoma (HNSCC) lines
1823. Phase I evaluation of STA-1474, a pro-drug of the novel Hsp90 inhibitor STA-9090, in dogs with spontaneous cancer
1824. Blood-brain barrier permeable Hsp90 inhibitor reduces soluble tau burden and rescues tau-dependent phenotype in a mouse model of tau accumulation
1825. The effects of a novel Hsp90 inhibitor——SNX-2112 on hepatis metablic enzymes in rats
1826. Demonstrating preclinical efficacy of AUY922, a novel Hsp90 inhibitor, alone and in combination with standard chemotherapy or radiation in esophageal …
1827. Cover Picture: Discovery and Biological Activity of 6BrCaQ as an Inhibitor of the Hsp90 Protein Folding Machinery (ChemMedChem 5/2011)
1828. Preclinical investigation of the Hsp90 inhibitor, ganetespib, in combination with FDA-approved cytotoxic agents for their potential anti-tumor effects on human …
1829. 4-Amino-substituted 5-resorcinol-isoxazole derivatives, a novel class of Hsp90 inhibitor: Synthesis and evaluation of in vitro activity
1830. Abstract# 4712: The Hsp90 inhibitor IPI-504 inhibits proliferation and tumor growth of HER2 overexpressing breast cancer cells with acquired trastuzumab resistance
1831. Abstract C91: Pharmacodynamic analysis of the Hsp90 inhibitor STA‐9090 in a lung cancer xenograft model supports an infrequent dosing schedule in the clinic
1832. Targeting angiogenesis and tumor growth with the Hsp90 inhibitor NVP-AUY922 in a model of pancreatic cancer: impact on cMet, VEGFR2 and PDGFR signaling
1833. IPI-504, a selective Hsp90 inhibitor is biologically active and tolerated in combination with trastuzumab in preclinical models of HER2 positive tumor xenografts
1834. Enhancement by Hsp90 inhibitor of PGD2-stimulated HSP27 induction in osteoblasts: suppression of SAPK/JNK and p38 MAP kinase
1835. Hsp90 inhibitor SNX-2112 inhibits cell growth by regulating Bcl-2 family proteins and cyclin proteins in MCF-7 cells
1836. Identification of the circRNA-miRNA-mRNA regulatory network of Hsp90 inhibitor-induced cell death in colorectal cancer by integrated analysis
1837. Preclinical efficacy of STA-12-8666, an Hsp90 inhibitor-targeted SN-38 conjugate, in small cell lung cancer (SCLC).
1838. BAG3‐dependent expression of Mcl‐1 confers resistance of mutant KRAS colon cancer cells to the Hsp90 inhibitor AUY922
1839. First-in-human phase I study of an oral Hsp90 inhibitor, TAS-116, in patients with advanced solid tumors
1840. P03. 09 AUY922, A NOVEL Hsp90 INHIBITOR EFFECTIVE AGAINST ABC-DLBCL AND MALT LYMPHOMA CELLS HARBORING GENETIC ALTERATION …
1841. Abstract# 4686: The molecular and biological effects of KW\# 8722; 2478, a novel non-ansamycin Hsp90 inhibitor, on multiple myeloma cells having various IgH …
1842. C1-07: IPI-504, a novel Hsp90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines.
1843. First-in-human phase I study of an oral Hsp90 inhibitor, TAS-116, in advanced solid tumors.
1844. C-terminal Hsp90 inhibitor, L80, targets cancer stem cell (CSC)-like property and suppresses metastasis via JAK/STAT3 inactivation in triple-negative breast cancer
1845. Abstract# 5650: The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma by downregulation of the prosurvival ER chaperone BiP …
1846. Hsp90 inhibitor 17-AAG plays an important role in JAK3/STAT5 signaling pathways in HTLV-1 infection cell line HUT-102
1847. Evaluating the Therapeutic Effect of an Hsp90 Inhibitor in Mouse Models of Alzheimer’s Disease
1848. 5.26 Hsp90 Inhibitor Restores P53-Mutated MEC1 Chronic Lymphocytic Leukemia Cell Sensitivity to Fludarabine by Downregulating DNA Repair and Endoplasmic …
1849. Novel Hsp90 Inhibitor C086 Potently Inhibits Non-Small Cell Lung Cancer Cells As A Single Agent Or In Combination With Gefitinib
1850. Combination immunotherapy integrating Hsp90 inhibitor 17-DMAG reconditions the tumor microenvironment for improved T cell recruitment and anti-tumor efficacy …
1851. 1622P Heat shock protein 90 (Hsp90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor …
1852. Hsp90 inhibitor, NVP-AUY922, improves myelination in vitro and supports the maintenance of myelinated axons in neuropathic mice
1853. Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (Hsp90) inhibitor XL888 in advanced BRAFV600 mutant melanoma.
1854. ET-41. A NOVEL Hsp90 INHIBITOR, NVP-HSP990, TARGETS CELL CYCLE REGULATORS TO PRODUCE AN ANTI-GLIOMA EFFECT IN OLIG2-EXPRESSING …
1855. Abstract# 1855: The novel Hsp90 inhibitor NVP-AUY922 reduces insulin-like growth factor receptor type 1 expression and lowers migration rate in triple-negative …
1856. Hsp90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators
1857. … # 4687: OSU-HDAC42, a novel HDAC inhibitor, exhibits biologic activity against human and canine malignant mast cells through both histone dependent and Hsp90 …
1858. Erratum to: A novel small molecule Hsp90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo
1859. Abstract# 2937: A purine scaffold heat shock protein 90 (Hsp90) inhibitor destabilizes BCL6 and has specific anti-tumor activity in BCL6 dependent lymphomas in vitro …
1860. Abstract B80: Hsp90 inhibitor SNX‐2112 and prodrug SNX‐5422 (PF‐04929113) inhibit key signal pathways Akt, Src and STAT3 and reactivate tumor suppressor …
1861. Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
1862. … study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble Hsp90 inhibitor, 17-AAG, in …
1863. Abstract LB-289: Synthetic Hsp90 inhibitor, PF-04928473 and prodrug PF-04929113, demonstrates potent antitumor activity in head and neck cancer by inhibiting …
1864. Assessing the Impact of HER2 Status on the Antitumor Activity of an Hsp90 Inhibitor in Human Tumor Xenograft Mice using Pharmacokinetics-Pharmacodynamic …
1865. Preclinical Testing Demonstrates Striking Efficacy of STA-12-8666, an Hsp90 Inhibitor–Targeted SN-38 Conjugate, in Small Cell Lung Cancer: Small Cell Lung …
1866. Re: First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin Hsp90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
1867. Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells
1868. A novel Hsp90 inhibitor induces metabolic oxid